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ABSTRACT 
 Breast cancer chemotherapeutics are only 50% successful due to 
chemoresistance mechanism of cancer cells. FOXO3, a tumor suppressor protein, is 
involved in the regulation of several cell death-related genes; however, the extent of 
FOXO3 regulation in chemoresistance mechanism is not fully understood. 
 In this study our aim was to characterize the potential crosstalk between FOXO3 
and NF-kappaB pathway with a special focus on IKK-FOXO3 interaction in relation to 
chemoresistance mechanism. For this purpose, we have used chemoresistant (MDA-
MB-231) and chemosensitive (MCF-7) breast cancer cell lines treated with paclitaxel 
(20nM) or cisplatin (30uM). Administration of 30uM cisplatin induced FOXO3-
dependent apoptosis in MCF-7 cells as indicated by RNA interference studies. 
Following the analysis of NF-kappaB pathway elements by immunoblotting and 
overexpression studies, we identified the physical interaction between IKK-beta and 
FOXO3 by co-immunoprecipitation. We have shown that IKK-beta sequesters FOXO3 
in the nucleus promoting chemoresistance in MDA-MB-231 cells. Additionally, 
imbalance between FOXO3 and IKK-beta levels induced autophagy rather than 
apoptosis in FOXO3 overexpressing MDA-MB-231 cells. We have also studied the 
effect of p53 on FOXO3 levels and showed p53-dependent FOXO3 inhibition in 
colorectal cancer cells. This is the first study describing FOXO3 regulation by IKK-beta 
in detail and showing that FOXO3/IKK-beta ratio may influence the cellular decision of 
apoptosis or autophagy. 
 In view of the results obtained, NF-kappaB pathway-FOXO3 crosstalk has been 
discussed and the interaction between FOXO3 and IKK-beta is proposed as a target for 
therapeutic intervention.  
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IKK’NĐN FOXO3 ÜZERĐNDEKĐ ETKĐSĐNĐN ARAŞTIRILMASI: ĐLAÇ 
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ÖZET  
 Kanser hücrelerinin ilaç direnci nedeniyle, meme kanseri tedavisinde kullanılan 
kemoterapi ilaçları yalnızca %50 başarı sağlamaktadır. Bir tümör baskılayıcı olan 
FOXO3, bir çok hücre ölümü ile ilişkili genin düzenlenmesinde yer almaktadır, ancak 
ilaç direncinde FOXO3’ün düzenlenmesi kapsamlı olarak tamamen anlaşılamamıştır. 
 Bu çalışmadaki amacımız, ilaç direnç mekanizmasında IKK-FOXO3 ilişkisini 
ele alarak FOXO3 ve NF-kappaB arasındaki olası çapraz etkileşimi karakterize 
etmektir. Bu amaçla, ilaca dirençli (MDA-MB-231) ve hassas (MCF-7) meme kanseri 
hücre hatlarını 20nM paklitaksel ve 30uM sisplatin kullanarak tanımladık. RNA 
interferans çalışmalarına göre 30uM sisplatin tatbiki MCF-7 hücrelerinde FOXO3-
bağımlı apoptozu tetiklemiştir. NF-kappaB yolak elementlerinin analizini takiben, ko-
immünopresipitasyon yöntemiyle IKK-beta ve FOXO3 arasındaki fiziksel etkileşimi 
tespit etmiş ve IKK-beta’nın FOXO3’ü nükleus’ta tutarak MDA-MB-231 hücrelerinde 
ilaç direncini destekledigini belirlemiş bulunmaktayız. Ek olarak, FOXO3 ve IKK-beta 
seviyeleri arasındaki dengenin bozulması da FOXO3’ün yüksek ifade ettirildiği MDA-
MB-231 hücrelerinde apoptoz yerine otofajiyi teşvik etmektedir. Ayrıca p53’ün FOXO3 
üzerindeki etkisin de çalışarak, kolorektal kanser hücrelerinde p53-bağımlı FOXO3 
inhibisyonunu göstermiş bulunuyoruz. Bu çalışma, IKK-beta tarafından gerçekleştirilen 
FOXO3 düzenlenmesini ayrıntılı olarak açıklayan ve FOXO3/IKK-beta oranının 
hücrenin apoptoz veya otofajiye karar vermesinde etkili olduğunu gösteren ilk 
çalışmadır. 
 Elde edilen sonuçlara bağlantılı olarak, NF-kappaB yolağı-FOXO3 çapraz 
etkileşimi tartışılmış ve ileride yapılması öngörülen çalışmalar sunulmuştur. 
Yayımlanan güncel veriler ışığında, FOXO3 ve IKK-beta arasındaki etkileşimin 
terapötik müdahalede hedef olacağı öngörülmektedir.  
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1.  ITRODUCTIO 
1.1. Cancer 
 The term ‘cancer’, includes more than 200 different diseases. When we consider 
its incidence and mortality, while ignoring the biological and clinical differences, cancer 
can be divided into five major groups: carcinoma; cancers arising from epithelia, 
sarcoma; in supportive and connective tissues such as bones, tendons, cartilage, muscle, 
and fat, myeloma; in the plasma cells of bone marrow, leukemia; in bone marrow, 
lymphoma; in the glands or nodes of the lymphatic system (specifically spleen, tonsils, 
and thymus). 
 
 The most common type of cancer is carcinoma regarding the rate of death. Lung 
cancers are the most important problems in both genders with 18,2% mortality 
worldwide and 22,5% in Turkey (Figure 1. 1). Breast cancer for women, on the other 
hand, takes the first place in mortality in both Turkey and the rest of the world. Every 
year, more than a million people are diagnosed with breast cancer. Especially in Turkey, 
25% of all cancers diagnosed in females are breast cancer [1]. Cancer incidence hardly 
changes in the century and shows variations between different populations in the 
different parts of the world reflecting different environmental effects [2-6]. 
 
 1.1.1. Carcinogenesis 
 Cancer is thought to be primarily an environment
fact that 90-95% of the cancer cases are based upon environmental factors and only 5
10% due to genetics. Environmental factors such as dietary habits (30
usage (25-30%), infections (15
lack of physical activity and environmental pollutants, can contribute to cancer 
 
 The environmental pollutants or chemicals involved in cancer formation are 
generally called ‘carcinogens’. Since cancer have 
‘promotion’ phases, sometimes those chemicals can be named as ‘co
(initiative) or only ‘carcinogen’ (promoting). 
mutagens, and then promoted by enhancer or/and suppressor ag
proliferation-related signals. At this stage, cells are still differentiated with the 
uncontrolled proliferation ability which results in the formation of oversized and 
progressively disorganized tissue mass. Following that stage, divi
unable to repair mutations occurred during unlimited cell divisions. This sequential 
Figure 1. 1. Lung and breast cancer mortality in Turkey and worldwide (the data 
were obtained from the International Agency for Research on Cancer, Cancer 
incidence, Mortality and Prevalence Worldwide 2008, World Health Organization)
2 
-related disease because of the 
-20%), ionizing and/or non-ionizing radiation (10%), 
-in the beginning
First, differentiated cells are initiated by 
ents which regulates 
-
-35%), tobacco 
[7]. 
- ‘initiation’ and 
-carcinogen’ 
ding cells become 
 
 division causes genetic instability and disrupt the DNA repair mechanism as well as the 
regulation of genes responsible from cell differentiation. In the end, de
cells start to get apart from the tissue and disperse via blood or lymph into the different 
parts of the body (metastasis) (
 
Figure 1. 2. 
 
 The agents causing cancer act as either a mutagen that can cause DNA 
mutations, or a sensitizer of several
to uncontrolled cell proliferation. Cells, in the process ‘carcinogenesis’, generally 
comprise several changes at the molecular level: genetic instabilization, DNA 
deletions/mutations and accumulation of g
alterations generally cause the formation of complex and new protein signaling 
networks which represents the characteristics of human cancers. These characteristics 
are basically: 
 
• Increased cell proliferation 
• Insufficient apoptosis
• Immortalization (growth beyond replicative senescence)
• Altered metabolism
• Genomic instability
• Altered cell and tissue differentiation
• Invasion into different tissues disturbing the tissue architecture
• Sometimes metastasis into local lymph nodes and/or distant tissues.
 
3 
Figure 1. 2) [8]. 
The main stages of carcinogenesis in somatic cells.
 endogenous/exogenous growth signals that can lead 
enetic and epigenetic differences. Those 
(often autonomous) 
 
 
 
 
 
-differentiated 
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 Cells that have those features are called as ‘malignant neoplasia’ or ‘malign 
cancer’ and usually fatal. On the other hand, ‘benign cancers’ are generally neither 
invasive and metastatic nor immortalized. They are mostly well differentiated and 
unable to proliferate as much as malignant tumors. 
1.2. Cancer Therapy 
 In order to prevent the progression of cancer; surgery, irradiation, drugs or their 
combinations can be employed. Choosing the appropriate therapy strongly depends on 
the stage/type of the cancer. Lymphomas, leukemias, metastatic or advanced 
carcinomas and soft tissue cancers mostly require chemotherapy. 
 
 As a matter of fact, the aim of the chemotherapy in this century mostly focuses 
on promoting cancer cells for cell death, especially ‘apoptosis’, instead of trying to 
transform them into their healthy form. The relationship between apoptosis and 
therapeutics is one of the most important fields of research in cancer therapy because 
understanding how therapeutics work in different cell types can help to design more 
efficient and specific drugs. The number of therapeutics has been designed for years and 
these drugs function by inducing apoptosis by changing the intracellular signaling 
pathways. Although breast cancer is one of the most important research topics both in 
Turkey and the rest of the world, therapeutics in use are only 50% successful. The main 
reason is therapeutic resistance (chemoresistance) mechanisms which can block the 
effect of drugs or/and desensitize the cells against cellular death signals. Cancer cells 
can build up chemoresistance either in the course of therapy or they already have innate 
resistance genotypically. Therefore, studies focusing on the resistance mechanisms have 
become more essential for the last decades [1, 9-11]. 
1.2.1. Cisplatin 
 Cisplatin (CDDP, H6Cl2N2Pt, (SP-4-2)-diamminedichloridoplatinum)
  is an 
inorganic compound (Figure 1. 3) and one of the most effective drugs to treat testicular, 
 ovarian, breast, bladder, and neck cancers 
synthesis of Cisplatin starting with K
 When Cisplatin is applied to the cells, only about 1% of the drug can reach the 
nucleus. Because of the 
is hydrolyzed by the cytoplasmic hydrolases
Charged Cisplatin attacks to the polar N7 nitrogen in the guanine nucleotides to form a 
covalent bond making 1,2 (GpG) intrastrand crosslinks
Cisplatin to DNA induces a 60
major groove and causes a widening of the minor groove 
are thought to be the primary cause of cisplatin cytotoxicity. The platinum center of 
cisplatin can also bind to the 
crosslinks which mainly prevent chromatin remodeling necessary for DNA transcription 
[17]. 
 
 Although, cisplatin is widely used in chemoresistance studies 
vivo, cisplatin treatment has dose
develop a resistance to c
5 
[12]. For therapeutic applications, 
2[PtCl4] is a simple process in inorganic chemistry.
 
Figure 1. 3. The structure of Cisplatin 
 
low concentration of chloride ions in the cell, neutral cisplatin 
 generating a positively charged agent. 
 (Figure 1. 4) 
–80 degrees bend of the DNA in the direction of the 
[15-16]. These DNA adducts 
intracellular proteins and histones creating DNA
-limiting side-effects in vivo and cancer cells can 
isplatin [18].  
the 
 
[13-14]. Binding of 
-histone 
in vitro and in 
 Figure 1. 
1.2.2. Paclitaxel 
 Paclitaxel (Taxol, C
{[(2R,3S)-3-(benzoylamino)
5,20-epoxytax-11-en-2-yl benzoate
prostate, breast, head and neck tumors 
(Figure 1. 5) and it was first isolated from the Pacific yew tree 
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4. Mechanism of Cisplatin action. 
47H51NO14, (2α,4α,5β,7β,10β,13α)-4,10
-2-hydroxy-3-phenylpropanoyl]oxy}-1,7-
) is used to treat patients with ovarian, gastric, 
[19-22]. Paclitaxel is an organic compound 
Taxus 
 
-bis(acetyloxy)-13-
dihydroxy-9-oxo-
brevifolia. Now, 
 for therapeutic use, all paclitaxel compounds are produced by plant cell fermentation 
technology using a specific 
 
 When cells are treated with Paclitaxel, 5% of the drug can end up in the 
cytoplasm effectively [23]
and stabilizes the microtubule polymer st
disassembly (Figure 1. 6
centrosomes which is essential to achieve 
mechanism blocks the progression
checkpoint proteins. Prolonged cell cycle arrest then triggers apoptosis 
 
7 
Taxus cell line and purified by chromatography.
 
Figure 1. 5. The structure of Paclitaxel 
. Paclitaxel binds to the β-tubulin subunit of the microtubules 
ructure leading to the prevention of its 
) [24]. Additionally, it suppresses microtubule
the metaphase spindle configuration
 of mitosis and causes activation of the mitotic 
 
 
 detachment from 
. This 
[25-28]. 
 Figure 1. 
 Programmed cell death is the death of any cell in multicellular organisms that is 
mediated by an intracellular program. It confers fundamental functions for both plants 
and metazoa in their life cycle. Programmed cell death can be divided into three main 
subheadings: Apoptosis, Autophagy and Necrosis. 
chemotherapeutics do not cause necrotic cell death, we will be especially focusing on 
apoptosis and autophagy.
1.3.1. Type-I Cell Death: Apoptosis
 In mammalian cells, the proc
immune system function, tissue homeostasis and deletion of damaged cells. It is 
regulated by a diverse range
by various stimuli such as 
signals may either trigger or repress the apoptotic cell death.
 
 Apoptosis can be divided into several stages: initiation, execution and removal 
of the cell remnants. Basically, two separate pathw
‘extrinsic’, can start the initiation process. They then converge towards the execution 
8 
6. The mechanism of Paclitaxel action. 
1.3. Programmed Cell Death 
As physiologic concentrations of 
 
 
ess “apoptosis” is involved in tissue sculpturing, 
 of extracellular- and intracellular-originated signals caused 
chemotherapy, toxins, growth factors, and cytokines. These 
 
ays, often called ‘intrinsic’ and 
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pathway. The intrinsic pathway can be activated by internal signals, such as DNA 
damage caused by a chemotherapeutic drug, whereas the extrinsic pathway responds to 
external signals such as death-related ligands. We will mostly emphasize the molecular 
mechanism of the intrinsic apoptotic pathway. 
1.3.1.1. Initiation 
 Intracellular apoptotic signaling starts in response to a stress leading to cell 
death. These stresses, reported as “apoptosis inducers”, are: heat [29], radiation [30] 
infection [31-32] hypoxia [33] elevated calcium concentration [34-35] and DNA 
damaging agents [36]. 
 
 Before the execution step is precipitated, apoptotic signals should promote 
regulatory proteins to initiate the apoptosis pathway. These regulatory proteins in the 
intrinsic pathway basically target the function of mitochondria [37-38]. Cytochrome-c, a 
small heme protein that is associated with the inner membrane of the mitochondria, is 
one of the most important intermediates for apoptosis induction [39]. It has a net charge 
of 8+ at the physiological pH which allows it to establish electrostatic interactions with 
the heads of anionic phospholipids. Under normal conditions, cytochrome-c is attached 
to cardiolipin, which is a type of diphosphatidylglycerol lipid, on the outer surface of 
the inner mitochondrial membrane. This attachment keeps cytochrome-c from releasing 
out of the mitochondria under normal conditions [40]. In response to apoptotic stimuli, 
cytochrome-c oxidizes cardiolipin which results in a conformational change in the 
structure of cardiolipin and consequently dissociation of cytochrome-c (Figure 1. 7) 
[41]. The dissociated form of cytochrome-c floating between the mitochondrion inner 
and outer membranes is not adequate to start apoptosis. To trigger the apoptotic signal, 
cytochrome-c is to be released from the mitochondria by permeabilization of its outer 
membrane. Therefore, there are several hypotheses explaining the mitochondrial outer 
membrane permeabilization. 
 Figure 1. 7. Dissociation of cytochrome
1.3.1.1.1. Mitochondrial outer membrane permeabilization
1.3.1.1.1.1. Mitochondrial permeability transition pore
 PTP is defined as an increased permeability of mitochondrial membranes to the 
proteins that are approximately 1,5 kDa in molecular weight 
reported that pore opening on the outer membrane of mitochondria is associated with 
VDACs (voltage-dependent anion channels) which constitute the main pathway for 
metabolite diffusion through the mitochondrial membranes 
composed of three basic components: VDAC, inner membrane protein 
nucleotide translocator) and the matrix protein cyclophilin D (CyD). According to the 
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-c following apoptotic stimuli.
 (MOMP)
 (PTP) 
[42-43]
[44]. PTP is thought to be 
 
 
 
. In 1993, it was 
ANT (Adenine 
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theory, an apoptotic stimulus causes elevated calcium levels and PTP opening, 
consequently mitochondrial swelling, christae reorganization and outer membrane 
rupturing. This hypothetical process allows cytochrome-c and other intermembrane 
proteins to be released to the cytosol [45]. In contrary to this argument, another study 
showed that VDAC knockout cells can still release the equal amount of cytochrome-c 
during apoptosis indicating that cytochrome-c release is independent from VDACs [46]. 
Although several pieces of evidence exist for and against either model, the pore size of 
PTP alone is practically not adequate for cytochrome-c (12 kDa) to pass through if no 
membrane rupturing occurs. Hence, other hypotheses were raised proposing the 
involvement of Bcl-2 proteins in MOMP [47]. 
1.3.1.1.1.2. Protein Channels and Lipidic Pores 
1.3.1.1.1.2.1 Bcl-2 family 
 Bcl-2 (B-cell lymphoma 2) is the first member of the Bcl-2 family, and encoded 
by the BCL2 gene [48]. Bcl-2 family members share at least one of the four 
characteristic homology domains; BH1, BH2, BH3, BH4 and can be divided into three 
major groups depending on their function: antiapoptotic Bcl-2 family proteins (such as 
Bcl-2, Bcl-xl, Bcl-w, Mcl-1, Bfl1, Diva), proapoptotic Bcl-2 family proteins (such as 
Bax, Bak, Bok and Bcl-xs) and a group of proteins that share only BH3 domain (such as 
Puma, Noxa, Bid, Bad, Bim, Bik, Blk, Hrk, Bnip3 and Bmf). Third group members are 
known to act as proapoptotic proteins by binding and inhibiting the effect of 
antiapoptotic Bcl-2 proteins (Figure 1. 8) [49-50]. 
 Figure 1. 8. Bcl-2 Family member
 
 Under normal conditions, proapoptotic member Bax is mostly localized in the 
cytosol (or loosely attached to the outer membrane of 
and mitochondria) as a monomer and 
the mitochondria to form dimers, oligomers or high
12 
s. (BH: Bcl-2 Homology Domains, TM: 
Transmembrane domain) 
the endoplasmic reticulum (ER) 
apoptotic signals induce Bax to translocate onto 
-order multimers 
 
[51-53]. Another 
 proapoptotic member: Bak constantly resides on mitochondria and/or ER and undergoes 
series of structural changes in response to apoptotic signals 
on Bax and Bak are thought to be directly involved i
conformationally active forms of Bax and Bak can insert their transmembrane domains 
into lipid bilayers and be oligomerized through their exposed BH3 domains. Therefore, 
this oligomerization results in a lipidic pore opening or 
formation whose size increases gradually over time 
pore opening allows the release of big molecules up to 2 MDa (Megadalton) 
100 kDa in vivo which allow the r
1. 9) [61-62]. 
 
 
Figure 1. 9. Bax and Bak mediated MOMP. (MOM: Mitochondrial outer membrane, 
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[54-56]. Structural changes 
n MOMP. Studies showed that 
causes a proteinaceous channel 
[53, 57-60]. Bax
elease of cytochrome-c from the mitochondria (
IMS: intermembrane space) 
-mediated lipidic 
in vitro and 
Figure 
 
  Although the exact mechanism explaining the cytochrome
mitochondria is still unknown, ba
interactions among the Bcl
proposes that Bim, Puma and Bid 
Bak. Antiapoptotic proteins, on the other hand, may form stable complexes with 
activators to prevent Bax and Bak activation. Additionally, Bad, Noxa, Bmf, Bik/Blk 
and Hrk/DP5 –inactivators
Puma for apoptosis induction 
mediate apoptosis independent from Bim, Bid, and Puma. It is proposed that Bax and 
Bak are normally bound to antiapoptotic members. They become active when BH3
proteins bind to antiapoptotic
Bax and Bak (Figure 1. 
pore formation might be conjoint mechanisms depending on the apoptotic stimuli.
 
 
Figure 1. 
14 
-
sically there are two models that are based on physical 
-2 family members. The direct activation model 
-called as “activators”- can directly activate Bax and 
- can bind to the antiapoptotic proteins to displace Bim and 
[63]. In the other model (Model 2), Bax and Bak can 
 members with higher affinity leading to dissociation of 
10) [64]. Recently it is thought that PTP opening and lipidic 
10. Regulation of Bax and Bak in MOMP.
c release from the 
(Model 1) 
-only 
 
 
 
 1.3.1.2. Execution and removal of the cell remnants
 Following MOMP, cytochrome
as SMAC (Second Mitochondria
to the cytosol to activate Apaf
domain of Apaf-1 is folded onto the protein keeping Apaf
[65]. Cytochrome-c binding induces a conformational change on Apaf
oligomerization and the 
recruitment [66-67]. For active apoptosome action, pro
become active caspase 9. Two hypotheses pro
location for caspase 9 dimerization causing its auto
while pro-caspase 9 is in monomeric form 
cleaves and activates executioner caspases; caspase 3 and caspase 7 (
 
Figure 1. 
 
 The multiple biochemical and morphological changes during the execution 
phase are caused by the proteolytic cleavage of more than 300 cellular proteins by 
caspase 3 and other executioner caspases. DNA fragmentation is mainly mediated by 
Caspase Activated DNase (CAD) 
of DNA in between nucleosomes because of the condensed chromatin structure in the 
cell [72]. The formation
one of the characteristic features of apoptosis. Caspase cleavage of 
Kinase (FAK) and p21
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-c -and other proapoptotic signal molecules such 
-derived Activator of Caspase, DIABLO
-1. In the absence of cytochrome-
-1 in an auto
active apoptosome complex is formed with pro
-caspase 9 should be cleaved and 
pose that either apoptosome provides the 
-cleavage, or the cleavage occurs 
[68-69]. In each case, initiator caspase 9 
11. The execution phase of apoptosis. 
[70-71]. CAD can only cleave the 
 of these fragments is known as apoptotic DNA fragmentation, 
-associated Kinase (PAK2) causes loss of adhesion and 
)- are released 
c, oligomerization 
-inhibited state 
-1 leading to its 
-caspase 9 
Figure 1. 11). 
 
accessible sections 
Focal Adhesion 
16 
 
membrane changes [73-74]. Importantly, a phospholipid component; phosphatidylserine 
(PS) is normally restricted to the inner layer of the cell membrane by the enzyme 
“flippase”. In the presence of apoptosis stimuli, it is flipped to the outer layer of the cell 
membrane which provokes activated macrophages for the phosphatidylserine-dependent 
recognition. In addition to PS recognition, macrophages are further attracted by other 
chemotactic signals coming from the dying cell and perform phagocytosis for the 
removal of cellular debris [75]. 
1.3.2. Type-II Cell Death: Autophagy 
 Autophagy is an evolutionarily conserved self degradation system which 
degrades proteins, macromolecules, organelles and has an important role in 
development and differentiation [76-78]. 
 
 Three types of autophagy have by now been identified: macroautophagy, 
microautophagy and chaperone-mediated autophagy. In macroautophagy, an “isolation 
membrane” sequesters a small portion of the cytoplasm which includes organelles and 
soluble materials to form autophagosome. Then, autophagosome fuses with lysosomes 
to degrade the materials within. In microautophagy, without an autophagosome 
formation, lysosome engulfs a small part of the cytoplasm by itself. On the other hand, 
chaperone-mediated autophagy does not have any membrane reorganization, proteins to 
be degraded translocate to the lysosome with the involvement of chaperone proteins 
[79]. Here in this thesis, macroautophagy is referred to as simply “autophagy”. 
 
 Autophagy, similar to apoptosis, also consists of sequential steps: induction, 
autophagosome formation, autophagosome-lysosome fusion and degradation. 
1.3.2.1. Induction 
 Cellular stresses, such as amino acid starvation, are known to be strong 
autophagy inducers. One of the important components of amino acid signaling 
pathways is mTOR (mammalian target of rapamycin). mTOR is a serine/threonine 
protein kinase and involved in proliferation, motility, survival, transcription, protein 
17 
 
synthesis [80-82]. mTOR functions as a nutrient/energy/redox sensor within its 
complex: mTORC1 (mTOR Complex 1) which is composed of mTOR, Raptor 
(regulatory-associated protein of mTOR), mLST8/GβL (mammalian LST8/G-protein β-
subunit like protein), Pras40 (Proline-rich Akt substrate of 40 kDa) and DEPTOR (DEP 
domain containing mTOR-interacting protein) [83-86]. Under normal conditions, 
mTORC1 inhibits autophagy with the help of Rag GTPase, Rheb and Vps34 [87-88]. 
Although mTORC1 inhibition is essential to induce autophagy, additional factors were 
reported as autophagy regulators, such as Bcl-2 [89], oxidative stress [90], calcium [91] 
and BNIP3 [92]. 
 
 Under normal conditions, active mTORC1 interacts with “ULK1 kinase 
complex” which consists of ULK1 (unc-51-like kinase), mAtg13 (mammalian ortholog 
of Atg13 in yeast), FIP200 and Atg101. mTORC1 phosphorylates ULK1 and mAtg13 
to inhibit the membrane targeting of ULK1 kinase complex. During starvation, changes 
in cellular energy levels activate AMPK (AMP-activated protein kinase), and then 
AMPK inactivates mTORC1 [93]. In addition to mTORC1 inactivation, it was shown 
that AMPK also phosphorylates ULK1 on several sites which causes ULK1 activation 
to induce autophagy signaling cascade [94]. Following the dissociation of mTORC1 
from ULK1 kinase complex, active ULK1 starts to phosphorylate mAtg13 and FIP200 
on the sites that cause their activation and consequently autophagy induction (Figure 1. 
12) [95]. 
 
 Figure 1. 
 
 Some studies showed that under different stress conditions and/or in different 
cells, initiation of autophagy can follow ULK1
reports suggest that Atg13 and
autophagy independent from ULK.
1.3.2.2. Autophagosome formation
 Vps34 (vacuolar protein sorting protein 34, Class III PI3K) is a 
phosphatidylinositol (PI) 3
form phosphatidylinositol (3)
sequesters Beclin1 through their BH3 domain and disrupts the interaction between 
Beclin1 and Class III PI3K (Vps34). Following the induction of autophagy, signaling 
proteins such as JNK, phosphorylates Bcl
[98-99]. Beclin1 then binds to Vps34 and forms ‘PI3K core complex” with PI3K 
adaptor protein p150. Then, Atg14L is recruited to the
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12. Induction step of autophagy. 
-independent pathways 
 FIP200 may have a function to allow them to initiate 
 
 
-kinase which can phosphorylate phosphatidyl
-phosphate (PI3P). Under normal conditions, Bcl
-2 and results in its dissociation from Beclin1 
 complex and directs PI3K core 
 
[96-97]. These 
inositol to 
-2 
 complex to the local ER membrane since Atg14L has the high binding affinity to 
membrane curvature (Figure 1. 
 
Figure 1. 
 
 This localization and Atg14L 
PI3P production [101]. DFCP1 (double FYVE
promoting the omegasome formation (a platform of autophagosome formation). 
Additionally, the binding of WIPI2 (WD
phosphoinoside) helps for the maturation of omegasome and isolation membrane. 
Although PI3P production by Vps34 may occur elsewhere in the cell, WIPI2  
recognizes and localizes to the local pool of PI3P that is only produced by PI3K core 
complex (Figure 1. 14) [102]
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enhance the activity of Vps34 and correspondingly 
-domain-containing protein 1) binds PI3P 
-repeat protein 
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interacting with 
  
Figure 1. 
 
 The molecular mechanisms that lie beneath the expansion of isolation membrane 
are still poorly understood. However, two ubiquitin
known to be involved. 
 
 Ubiquitin is a 76 amino acid long protein (8,5 kDa). The aim of the ubiquitin 
conjugation system is to transfer 
catalyzed by E1, E2 and E3 enzymes (specific proteases) 
is first processed by E1 enzyme for the exposure of C
ubiquitin is transferred to E2 enzyme forming a thioester bond. Another protease, E3, 
recognizes the target protein and catalyzes the binding of ubiquitin to the l
of the target protein. The ubiquitin tag is a signal to direct target proteins to the 
proteasomal degradation. In autophagy, the conjugation of the autophagy
proteins follows a similar strategy to the ubiquitin system.
20 
14. Autophagosome formation-II 
-like protein conjugation systems are 
ubiquitin to a target protein via sequential
[103]. The ubiquitin pre
-terminal glycine residue. Then, 
 
 
 reactions 
cursor 
ysine residue 
-related 
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1.3.2.2.1. Ubiquitin-like conjugation system 1 
 In the autophagy, the ubiquitin-like conjugation system is involved in the 
isolation membrane expansion. In the first conjugation system, C-terminal glycine 
residue of Atg12 is activated by Atg7 (E1-like enzyme) through a thioester bond in 
response to autophagic signals. After that, Atg12 is transferred to the lysine 149 residue 
of Atg5 by Atg10 (E2-like enzyme) involvement [104-105]. Atg12-Atg5 conjugate, 
further interacts with Atg16L and forms Atg12-Atg5/Atg16L1 complex. Through the 
homo-oligomerization of ATG16L, in mammalian cells it is thought that a 800 kDa 
multimer of Atg12-Atg5/Atg16L is formed (Figure 1. 15, Conjugation system I) [106-
107]. 
 
 Importantly, it is reported that autophagy may occur in an independent manner 
of Atg5 and Atg7 [108-110]. Atg12–Atg5/Atg16L complex is not sufficient to coat the 
autophagic vesicle in some cell types, but Atg16L complex specifies the accurate 
localization of LC3 and promotes its lipidation [111-112]. 
1.3.2.2.2. Ubiquitin-like conjugation system 2 
 In healthy mammalian cells, LC3 (Microtubule-associated protein light chain 3)  
is synthesized as pro-LC3. Atg4B (a cysteine protease, E1-like enzyme) immediately 
cleaves the C-terminal 22 residues for the exposure of its C-terminal glycine  to form 
soluble cytosolic LC3-I [113]. Then, with the help of E2-like enzyme Atg7, LC3 is 
conjugated to another E2-like enzyme Atg3 [114]. In response to autophagic signals, it 
is proposed that LC3-Atg3 conjugate is recruited by Atg16L1 complex which resides on 
a yet undetermined membrane [111]. Thus, LC3-I is conjugated to the head group of a 
phospholipid: phosphatidylethanolamine (PE) by Atg3 (Figure 1. 15, Conjugation 
system II). Because Atg12–Atg5 in Atg16L complex acts as an E3 enzyme at the final 
step of this conjugation system, Atg12–Atg5 is proposed to be the E3-like enzyme 
[115]. The lipidated form of LC3 (LC3-II) then associates newly forming 
autophagosome membranes (Figure 1. 16) [116]. 
 
  
Figure 1. 15
 
 Although there are several studies proposing the omegasome as a platform of 
autophagosome formation, it must be said that it is still not clear whether only ER 
membrane is directly used in autophagy. Some studies showed that the membranes of 
autophagosome may also be derived from golgi, mitochondria or plasma 
[117-123]. 
 
Figure 1. 16
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 Once autophagosomes are formed, a novel protein FYCO1 (FYVE and coiled-
coil [CC] domain containing 1) binds to LC3 and Rab7 (a GTPase) to form an adaptor 
complex. LC3 binds to microtubules and moves the autophagosome along microtubules 
toward lysosomes with the help of dyneins [124-127]. 
1.3.2.3. Autophagosome-lysosome fusion and degradation 
 The first contact between autophagosome and lysosome is mediated by a big 
protein complex called “HOPS complex” (homotypic fusion and vacuole protein sorting 
complex: Vps11, Vps16, Vps18, Vps33, Vps39, Vps41). Then, membrane anchored 
protein SNARE (soluble N-ethylmalemide-sensitive factor attachment protein receptor) 
adjoins its transmembrane domain to fuse two lipid bilayers [128]. Following the fusion 
of lysosome and autophagosome, cytoplasm-derived proteins and the inner membrane 
of autophagosome are finally degraded by lysosome-derived hydrolases. 
1.4. Diminished Apoptosis/Autophagy in Cancer 
 Decreased response to death related signals may lead to genomic instabilization. 
During the sequential divisions, the diminished rate of cell death causes hyper-
proliferation and serious tumor characteristics like metastasis. As mentioned before, 
many cytotoxic drugs used in chemotherapy induce –mostly apoptotic- cell death. 
Although some degree of apoptosis may occur within the cancer tissue, it is not at the 
same rate as in normal cells. Thus, further decrease in apoptotic response in cancer cells 
contributes to drug resistance. Diminished apoptosis is often caused by the overactivity 
of survival signaling pathways rather than the primary alterations in apoptotic pathways. 
Bcl-2, for instance, is over-expressed in a wide range of carcinomas such as breast and 
prostate cancers. Alternatively, cancers mostly have high levels of Bcl-xl protein. On 
the other hand, Beclin 1 was reported as deleted in many cancers suggesting that 
autophagy might be another tumor suppressor mechanism –similar to apoptosis- in 
cancers [129-130]. 
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 To understand the chemoresistance and mechanism of cell death, identifying the 
upstream events of the cell death signaling is essential. Cell death inducing stimuli 
(chemotherapeutics) first activates various transcription factors to start protein signaling 
cascade leading to cell death or survival. In this thesis, two transcription factors, their 
main pathways and possible intersections of two pathways were examined. 
1.5. FκB Pathway 
 NFκB (Nuclear Factor-kappa B) consists of five cellular proteins: p50/p105 
(NFκB1), p52/p100 (NFκB2), p65 (RelA), RelB and c-Rel. These proteins function as 
homo- or heterodimers and the most prevalent complex among the combinations is 
p65:p50 heterodimer. The subunits p50 and p52 are derived from the proteolytic 
cleavage following mono-ubiquitination of the C-terminal domains from the precursor 
molecules p105 and p100 respectively [131]. Cleaved p50 or p52 binds to p65, c-Rel or 
RelB to form the active NFκB complex. p50 and p52 do not have transactivation 
domains, unlike p65, RelB and c-Rel. Nevertheless, they play critical roles in 
modulating the specificity of NFκB function. 
 
 In unstimulated, healthy mammalian cells, Rel subunits predominantly reside in 
the cytoplasm, bound to IκB family proteins (IκB-α, IκB-β, IκB-ε) which function by 
masking the nuclear localization signal (NLS) found on NFκB subunits. IκB-α is 
partially effective for blocking NLS meaning that it can enter the nucleus with NFκB 
subunits. However, it contains a nuclear export signal (NES) that causes the rapid 
export of the complex back to the cytoplasm [132]. IκB-β can also bind NFκB in the 
nucleus without displacing it from DNA. Some studies propose that IκB-β may have a 
function for the stabilization of DNA-NFκB complex by preventing the displacement of 
NFκB [133-134]. Other studies, on the other hand, point out that loss of IκB-β prolongs 
NFκB activity in certain cells [135-136]. These studies indicate that the inhibition of 
NFκB is highly tissue and stimuli specific. 
 
  In response to activators of the NFκB pathway, 
and Ser36 residues by Iκ
IKKα, IKKβ, and IKKγ (NEMO). IKKα and IKKβ have the serine/threonine kinase 
activity, on the other hand IKKγ is known as the regulatory protein of the complex 
[137]. Besides IκB proteins, IKK complex has other important cellular targets such as 
FOXO3 and Htt (Huntingtin) 
 
 
 After IκB is phosphorylated by IKK, it is subjected to proteosomal degradation 
following ubiquitination 
transporter proteins importin
NFκB into the nucleus via dynein and dynactin complex 
NFκB binds to its consensus sequences on DNA, known as “
YYCC-3’, R; a purine base, N; any base, W; adenine or thymine and Y; pyrimidine 
base) [145-146]. After the 
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IκB is phosphorylated at Ser32 
B kinase (IKK) (Figure 1. 17). IKK consists of three subunits: 
[138-140]. 
Figure 1. 17. NFκB Pathway 
[141-142]. The exposure of the NLS on NF
-α3 and importin-α4 to bind to its NLS and to transport 
[143-144]
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site) slightly bends towards the major groove to be recognized by other transcription 
activators [147]. 
 
 Theoretically, there are 15 possible dimers of NFκB subunits and each couple 
may have some preference for different κB sites depending on their affinities [148]. 
However, transcriptional specificity is not necessarily conferred by affinity differences 
of the subunits because each dimer can undergo conformational changes to interact with 
DNA. This suggests that different NFκB dimers can bind to the same κB site with 
comparable affinities [149]. This flexibility allows NFκB to regulate the transcription of 
a wide range of genes. NFκB itself is involved in the regulation of more than 300 genes 
of various biological processes including immune response, inflammation, cell growth, 
survival, and development [150]. 
 
 While NFκB has a basal level activity in normal cells, the activity of NFκB 
pathway in cancer cells may vary and frequently causes increased expression of pro-
survival genes. For instance, NFκB-mediated increase in Bcl-2 and/or Bcl-xl expression 
allows these proteins to gain anti-apoptotic function in addition to basal pro-survival 
functions they have in normal state. 
 
 Pro-apoptotic Bcl-2 members Bax and Bim are also regulated by NFκB but in a 
different way. In mammalian cells, heterodimerization of p65/p50 suppresses the 
promoter activity of Bax and p52/p52 homodimers prevent Bim transcription [151-152]. 
Therefore, this regulatory capacity of NFκB may lead to decreased apoptotic response 
in most cancers. NFκB is also involved in autophagy regulation. It is known that NFκB 
pathway is activated following autophagy; however the role of NFκB in autophagy 
regulation is still poorly understood as there are controversial studies reporting the 
inhibitor or the activator effect of NFκB in the regulation of autophagy [153-158]. 
Importantly, Bax can cleave Beclin1 causing a reduction in the autophagy response 
[159]. 
  Forkhead family which is characterized by a conserved DNA
(the Forkhead box, or FOX) comprises more than 100 members in humans. They 
classified from FOXA to FOXR depending on their sequence similarity. Forkhead 
(FOXA), the first member and the founder of the family, was first identified in 
Drosophila as a gene whose mutation causes the development of fork
structure [160]. Forkhead proteins are also called as “winged helix” proteins because 
their DNA-binding domain consists of three 
loops like butterfly wings.
 
 Class “O”, FOXO transcription factors consist of FOXO1 (FoxO1a or FKHR), 
FOXO3 (FoxO3a/FKHRL1), FOXO4 (AFX) and FOXO6. They all first identified as 
insulin/PI3K/Akt pathway
conserved winged-helix domain which mediates its binding to DNA.
 
 Our main focus, FOXO3 
processes and acts as a tumor suppressor in various cancers. It is especially involved in 
the transcriptional regulation of cell death
Noxa [164], LC3 [165], Beclin 1 
[167], cyclinD [168] and GADD45α 
 
 
 
 In the absence of growth signals, FOXO3 is localized in the nucleus as a potent 
transcriptional activator and binds to the conserved DNA motif 5’
[170-171]. The well known control mechanism of FOXO3 localization is especially 
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1.6. Forkhead Family and FOXO3 
α-helices flanked by two characteristic 
 
-regulated transcription factors [161]. They
 
(Figure 1. 18) has an important role in several cellular 
-related proteins Bim [162]
[166] and cell cycle arrest proteins such as p27KIP1 
[169]. 
Figure 1. 18. Structure of FOXO3 
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 phosphorylation. External st
phosphorylation at conserved serine/threonine residues in the nucleus. 
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 Akt, AMPK, ERK1/2 and IKKβ are thought to be the most potent upstream 
kinases that interfere with the function of FOXO3 in the nucleus [174, 184-186]. 
Although subcellular localization of FOXO3 is the main regulatory system, altering 
FOXO3 protein levels can also have dramatic effects. It was shown that overexpression 
of wild type FOXO in C. Elegans and Drosophila can extend lifespan [187-189], while 
loss of FOXO increases cancer in mammals [190-191].  
 
 Because FOXO3 upregulates several cell death proteins, inactivation of FOXO3 
is directly related to chemoresistance and longevity [192-193]. It has been shown that 
active FOXO3 overcomes the resistance against various drugs such as 
Gefitinib/ZD1839 in breast cancer cells [194-195], Imatinib/STI571 and doxorubicin in 
chronic myelogenous leukemia [196-198], and cisplatin in colon cancer cells [199]. 
1.7. Aim of the Study 
 Approximately 30% of the women diagnosed with early-stage disease in turn 
progress to metastatic breast cancer, for which therapeutic options are limited due to the 
partial effectiveness of the drugs. Chemoresistance, resistance to the chemotherapeutic 
drugs, is the major obstacle to the effective treatment of many types of tumors including 
breast tumors. Paclitaxel and cisplatin are important agents in the treatment of 
malignant breast cancers and the first-line chemotherapy generally includes paclitaxel 
and/or cisplatin. Although those chemotherapeutics can alter the growth of tumors, in 
most cases their effect is limited and not long lasting as mentioned before. Therefore, 
there is a significant need for understanding the protein signaling mechanisms involved 
in chemoresistance in order to develop new therapy strategies to improve the response 
rates and potentially extend survival. 
 
 In the scientific literature, the major protein signaling pathways involved in 
cell death were mostly identified with their main elements; however, signaling 
pathways are not isolated systems and they can interact in a number of ways which 
forms sophisticated signaling networks. On this account, understanding the crosstalk 
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between those identified pathways is fundamental for designing molecularly targeted 
therapy against cancer. 
 
 The aim of this study was to investigate the potential crosstalk between 
FOXO3 and NFκB pathway and to clarify the effect of this crosstalk on cell death 
response which is associated with chemoresistance. For that purpose, we focused on 
IKK-FOXO3 interaction and used two metastatic breast cancer cell lines as a model of 
chemoresistance: (1) MCF-7 which retains several characteristics of differentiated 
mammary epithelium and (2) MDA-MB-231 which shows highly dedifferentiated 
behavior. We first used paclitaxel or cisplatin as therapeutic agents to simulate the effect 
of first-line therapy in differentiated and dedifferentiated cells and then identified the 
physical interaction between IKK and FOXO3 which determines the cellular response 
to cisplatin resulting in chemoresistance or chemosensitivity. 
Specifically, the aim was; 
a) to investigate cell cycle arrest or apoptosis upon chemotherapeutic drug 
treatment and to understand the role of Bcl-2 family proteins and DNA damage 
response by FACS and immunoblotting analyses, 
b) to understand NFκB and FOXO pathways by using FOXO3 siRNA technology, 
enforced expression of FOXO3, immunoblotting and EMSA. 
c) to identify the role of IKK and its subunits on cell death response by chemical 
inhibition of IKK complex or enforced expression of IKK subunits.  
d) to identify the involvement of death response (autophagy or apoptosis) by 
fluorescent microscopy, FACS and immunoblotting analyses 
e) to understand the role of p53 on FOXO regulation by either ectopic expression 
of p53 in p53 knockout/p53 mutant cells or chemical inhibition of p53 in p53 
wildtype colorectal and breast cancer cells. 
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2.  MATERIALS AD METHODS 
2.1. Materials 
2.1.1. Chemicals and media 
 All chemicals and growth media used in this study are listed in Appendix A. 
2.1.2. Antibodies and enzymes 
 All antibodies used in immunoblotting, FACS analysis and EMSA are listed in 
Appendix B. 
2.1.3. Molecular biology kits and reagents 
 Molecular biology kits for gene transfection, plasmid isolation and protein 
analysis are listed in Appendix C. 
2.1.4. Vectors 
 The maps of the expression vectors used are shown in Appendix D. 
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2.1.5. Oligonucleotides 
 FOXO3 consensus oligonucleotide for EMSA experiments, GADD45α PCR 
primers and GAPDH PCR primers are listed in Appendix E. 
2.1.6. Buffers and solutions 
 All buffers and solutions (manually prepared) are listed in Appendix F. 
2.1.7. Equipment and computer software 
 Equipments and computer software used are listed in Appendix G. 
2.2. Methods 
2.2.1. Cell lines 
 MCF-7 (HTB-22, ATCC) and MDA-MB-231 (HTB-26, ATCC) breast 
adenocarcinoma cells were grown in DMEM with 2 mM L-glutamine, 10% FBS, 100 
IU/ml penicillin and 100 µg/ml streptomycin in a humidified incubator at 37oC and 5% 
CO2; HCT-116 wild type (CCL-247, ATCC) and p53
-/- HCT116 colorectal carcinoma 
cells (kindly provided by B Vogelstein, Johns Hopkins University, Maryland) were 
grown in McCoy’s 5A with 2 mM L-glutamine, 10% FBS, 100 IU/ml penicillin and 
100µg/ml streptomycin in a humidified incubator at 37oC and 5% CO2. 
2.2.2. Cell cycle analysis 
 Cultured cells were harvested by trypsin (0.05% Trypsin/0.53 mM EDTA) and 
washed once with cold PBS (pH: 7,4). Pellets were fixed with 5ml of 70% ethanol (v/v) 
for 15 minutes and washed again with cold PBS (pH: 7,4) followed by incubation with 
propidium iodide staining buffer (see Appendix F) in the dark for 45 minutes. Then, 
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500µl of cold PBS (pH: 7,4) were added to the incubating cells to dilute the PI 
concentration and labeled cells were analyzed by FACS. 
2.2.3. Cell death, viability and proliferation assays 
 Cell death response was assessed by FITC-conjugated Annexin-V. Briefly, cells 
to be analyzed were incubated with Annexin-V staining buffer for 15 minutes and 
quantified by FACS on FlowJo software. In order to detect cell viability or cell 
proliferation, the cells (7500 cells/well) were seeded in 96-well plates and analyzed by 
MTT (Cell Proliferation Kit I) according to the manufacturer's instructions. Results are 
expressed as percentage of cell viability, proliferation or cell death. 
2.2.4. Cleaved caspase 3 staining 
 Cells were harvested and subjected to 3% formaldehyde (w/v) fixation for 10 
minutes. Fixed cells were incubated with Methanol (15 minutes) for permeabilization 
and washed with %0.5 BSA (w/v) containing FACS incubation buffer (see Appendix 
F). Cells were incubated for 1 hour with 1:400 anti-cleaved caspase 3 monoclonal 
antibody and then with 1:800 FITC-anti-rabbit secondary antibody for 30 minutes. After 
two washes with PBS (pH: 7,4), cells were subjected to FACS analysis on FlowJo 
software. 
2.2.5. Fluorescent Microscopy 
 Cells (50000 cells/well) were grown on sterile cover slides in cell culture 
conditions and fixed with cold Methanol:Acetone (1:1) for 15 minutes. Following three 
PBS (pH: 7,4) washes, cells were stained with DAPI by DAPI staining solution for 15 
minutes and slides were analyzed with Olympus B60 fluorescent microscope using 
required filters. 
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2.2.6. Transfections 
 For the transfection experiments, cells were grown to 50% confluency and 
transiently transfected with pECE-HA-FOXO3(wt) (kindly provided by Gregory J. 
Gores), pEGFP-FOXO3(S644A) (kindly provided by Mien-Chie Hung), pCMV-flag-
IKKβ, pCMV-HA-IKKα, pCMV-flag-IKKγ (kindly provided by Richard B. Gaynor), 
pEGFP-LC3 (kindly provided by D Gozuacik), pCMV-p53(wt) (kindly provided by B 
Erman) or mock vectors using Fugene6 or Metafectene-easy transfection reagents. 
Briefly, 6µl Fugene6 were added to 100µl serum-free DMEM which contains 2µg of 
plasmid DNA. Then, the mixture was incubated for 30 minutes at room temperature and 
added dropwise to the cells. MCF-7 cells were transfected with FOXO3-specific siRNA 
or negative control (non-silencing) siRNA by Hiperfect transfection reagent. Briefly, 
6µl Hiperfect reagent was added to 75ng siRNA containing 200µl serum-free DMEM 
and the mixture was briefly vortexed. Following 10-minute incubation at room 
temperature, the mixture was added dropwise to the cells. For FOXO3 silencing 
experiments, three sequential transfections were assessed to obtain a long term silencing 
effect. After the first transfection, the cells reached confluency in 2-3 days. Confluent 
cells were harvested; second and third transfections were performed during seeding. 
Transfected cells were verified by immunoblotting 48 hours after the transfection (after 
the third transfection in siRNA experiments). 
2.2.7. RA isolation 
 Cells in a 12-well plate were washed with cold PBS and scrapped off by 250µl 
Trizol, incubated in a 1,5 ml centrifuge tube for 5 minutes. Then, 100µl of chloroform 
was added and incubated at room temperature for another 5 minutes. The samples were 
centrifuged at max speed for 15 minutes (4ºC) and upper phase of the mixture was 
separated to a new tube. After adding 250µl of isopropanol, tubes were incubated at 
room temperature for 10 minutes and centrifuged at max speed for 10 minutes (4ºC). To 
wash the RNA pellet, supernatants were discarded and the pellets were washed first 
with 250ìl 80% ethanol and centrifuged at 7500g/5 minutes (4ºC). Pellets were dried on 
bench for 5 minutes and resuspended by 50µl DEPC-water. 
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2.2.8. Semi quantitative and quantitative PCR 
 The concentrations of isolated RNAs were quantified by spectrophotometric 
measurement using Nanodrop. For reverse transcriptase PCR, total RNA isolates (1µl) 
were incubated with Sensiscript RT kit for 1,5 hours at 37ºC in the PCR machine. For 
semi quantitative PCR, the reaction mixture (100ng cDNA, 1µM forward and reverse 
primers and Taq PCR Master Mix) was run for 25 cycles and amplified cDNAs were 
analyzed by agarose gel (1%) electrophoresis in 1X TBE buffer. For quantitative 
realtime PCR analysis, 30-40 cycles were performed with quantitech SYBRgreen kit. 40 
PCR cycles were run (each cycle contains 94ºC for 1 minute, 51ºC for 1 minute, 72ºC 
for 30 seconds) with an additional 94ºC 10-minute step in the beginning and a 72ºC 10-
minute for the final extension. The results were analyzed by Pfaffl equation method 
[200]. In both PCR experiments, GADD45α and GAPDH primers were used (see 
Appendix E). 
2.2.9. Total protein isolation 
 Treated cells were washed with cold PBS (pH: 7,4), scraped off the surface of 
cell culture plates in 1ml PBS (pH: 7,4) and transferred to 1,5ml centrifuge tubes. Cells 
were cold centrifuged for 30 seconds at max speed. Pellets were resuspended in 50µl 
cold complete lysis buffer (see Appendix F), vortexed and kept on ice for 20 minutes. 
Samples were then cold centrifuged and supernatants containing total proteins were 
stored at -80°C. 
2.2.10. Subcellular protein extraction 
 Following the cell scrapping and cold centrifugation, cell pellets were 
resuspended in 50µl hypotonic T1 buffer (see Appendix F) and kept on ice for 20 
minutes. After the cold incubation, tubes were centrifuged at max speed for 1 minute 
and supernatants containing cytoplasmic proteins were stored at -80°C. Pellets were 
resuspended in 20µl saline T2 buffer (see Appendix F) and incubated on ice for another 
20 minutes followed by cold centrifugation for 20 minutes at max speed. Supernatants 
containing nuclear proteins were stored at -80°C immediately. 
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2.2.11. Protein concentration determination 
 Protein concentrations of protein extracts were determined by Bradford reagent. 
Bovine serum albumin (BSA, stock solution: 1mg/ml) was used as the standard protein. 
Starting with 5µg BSA/well in 96-well plates, BSA was 1:1 diluted to constitute a 
standard graph, 1µl of samples were prepared simultaneously and 100µl of Bradford 
reagent were added to the wells. Absorbance was spectrophotometrically measured at 
595nm by a microplate reader with the first standard set as blank. Protein concentrations 
in the samples were then determined by extrapolating their absorbance values against 
the standard curve. For every new assay a new standard curve was generated. 
2.2.12. Immunoblotting 
 Total cell lysates were isolated with complete lysis buffer (see appendix F). 
Total cell lysates or subcellular fractions were separated on SDS-PAGE using running 
buffer and transferred onto PVDF membrane that has been activated in methanol for 30 
seconds. For this transfer step, freshly prepared transfer buffer (see Appendix F) was 
used. Membranes were blocked with blocking solution and incubated with indicated 
primary antibodies and required HRP-conjugated secondary antibodies in the antibody 
incubation solution. Proteins were finally analyzed using ECL Advance and exposed to 
Hyperfilm ECL. All critical blots and immunoprecipitation experiments were repeated 
at least three times. 
2.2.13. Densitometric analysis 
 Densitometric values for immunoblotting results were calculated by ImageJ 
software. 
2.2.14. Preparation of radiolabeled oligonucleotides 
 Complementary oligonucleotides (FOXO3 consensus, IGFBP IRS site. See 
Appendix E) were obtained separately (stock solution: 3mg/ml) and 2µl of each 
oligonucleotides were mixed and incubated in 46µl annealing buffer (see Appendix F) 
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first 4 minutes at 95°C, then 10 minutes at 70°C. Oligonucleotides were then left at 
room temperature to cool down and stored at -20°C. Complementary oligonucleotide 
was labeled with γ-32P-dATP (3000 Ci/mmol) by T4 polynucleotide kinase in the 
oligonucleotide labeling reaction mix (see Appendix F) and then purified on a Sephadex 
G-25 column. Sephadex G-25 columns were washed completely off its buffer first by 
gravitation, then by centrifugation twice at 3500rpm (1650g) for 2 minutes. Total 
reaction mix (50µl) was applied to the center of the column in an upright position. The 
assembly was centrifuged twice at 2300rpm (1100g) for 4 minutes. 
 
2.2.15. Electrophoretic Mobility Shift Assay (EMSA) 
 Cytoplasmic and nuclear proteins were separately isolated and nuclear extracts 
were subjected to EMSA as described before [201]. Briefly, 5µg of nuclear proteins 
were incubated 30 minutes at room temperature with 32P-labelled oligonucleotide 
probes in the EMSA incubation buffer. DNA–protein complexes were resolved on 6% 
non-denaturing polyacrylamide gels (see Appendix F). The gels were then dried and 
autoradiographed on X-ray films. For supershift assay, 1µl anti-FOXO3 antibody was 
added 10 minutes before the binding incubation was finalized. 
2.2.16. Co-immunoprecipitation 
 Cell lysates were isolated in complete lysis buffer (see Appendix F). 800-1000 
µg proteins were immunoprecipitated with 1µl (stock solution: 1mg/ml) anti-FOXO3 or 
anti-IKKβ primary antibodies at 4°C for 2 hours and captured by 50% slurry of protein 
G-Sepharose beads (50µl) in complete lysis buffer at 4°C for another 2 hours. 
Immunoprecipitates were then washed four times with complete lysis buffer. Finally, 
the beads were resuspended with 20µl of Laemmli sample buffer, boiled at 95°C for 5 
minutes and finally loaded into the wells of the polyacrylamide gel for immunoblotting 
analysis. 
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2.2.17. Statistical analysis 
 The statistical significance of the results was analyzed by Student’s t-tail test and 
*P<0.05, **P<0.01 and ***P<0.001 were considered statistically significant. 
2.2.18. Illustrations 
 All illustrations shown in “Introduction”, “Results” and “Discussion and 
Conclusion” sections were designed by the thesis author using Adobe Photoshop CS5, 
Irfanview and MS Office 2007 softwares. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
39 
 
 
 
 
 
 
 
3.  RESULTS 
3.1. Effect of Cisplatin or Paclitaxel treatment on cell viability and cell death in 
MCF-7 and MDA-MB-231 cells 
 In order to determine the cytotoxic effects of cisplatin and paclitaxel 
individually, we treated MCF-7 and MDA-MB-231 breast cancer cell lines with various 
concentrations of cisplatin or paclitaxel. Cell viability was then assessed by MTT assay 
(Figure 3. 1). At physiologically relevant concentrations of cisplatin (30µM) and 
paclitaxel (20nM), MTT results showed that MDA-MB-231 cells are more resistant to 
both chemotherapeutics (paclitaxel73%, cisplatin76% viability) than MCF-7 cells 
(paclitaxel59%, cisplatin64% viability). 
 
 
 
 Figure 3. 1. The effect of paclitaxel/cisplatin on cell viability. MCF
231 cells were treated with different paclitaxel concentrations 
concentrations (B) for 48 hours. 
results represent the mean (±SEM) values obtained from at least three different 
experiments with eight repeats (***=p<0.01).
 
 Because MTT assay works on the metabolic activity which can be variable in 
different cell lines, we also performed Annexin
paclitaxel treatment to monitor drug
we used FITC-conjugated Annexin
cells’ surface. Especially in physiologically relevant concentrations, 30µM 
20nM paclitaxel, 70% (for 
analyzed as Annexin-V positive, indicating 
MDA-MB-231 cells showed only 46% and 23% cell death respectively, in response to 
paclitaxel or cisplatin treatment. Depending on the results obtained and previously 
published studies, 30µM 
experiments [202]. 
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(A)
Cytotoxicity was determined by MTT Assay and 
 
-V staining 48 hours after cisplatin or 
-induced cell death (Figure 3. 2
-V protein which has a high affinity to PI on dying 
paclitaxel) and 36% (for cisplatin) of MCF
the cells undergoing cell death, whereas 
cisplatin and 20nM paclitaxel were u
 
-7 and MDA-MB-
 or cisplatin 
the 
). For that purpose, 
cisplatin or 
-7 cells were 
sed for further 
 Figure 3. 2. The effect of paclitaxel/cisplatin on cell death. MCF
cells were treated with indicated concentrations of 
hours, stained with FITC
3.2. Effect of Cisplatin or Paclitaxel treatment on cell cycle arrest
The period of growth is referred to as interphase and comprises three phases of the cell 
cycle: a gap phase (G1
dormant during mitosis; a 
doubled and the chromosomes are replicated; and a second gap phase (
 
 Paclitaxel is a potent in
phase of the cell cycle 
checkpoint [205]. To investigate the possible differences in MCF
cells regarding the cell cycle arrest, we t
12 and 24 hours and dyed with propidium iodide along with the untreated controls 
(Figure 3. 3). 85% of MCF
G2/M stage 24 hours after paclitaxel treatment. For both cell lines, the percentage of the 
cells that newly accumulated in the G2/M phase was approximately 35%. Prior to 
cisplatin treatment, while MCF
population, cisplatin treatment caused additional 37% cell accumulation (78%). 
However, MDA-MB-231 cells showed only 8% additional cell accumulation in the G1 
phase (46% 54%). 
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-Annexin-V and subjected to FACS analysis (**=p<0.05).
), in which the cells resume the biosynthesis which has been 
synthesis phase (S), in which the DNA content of the cell is 
hibitor of cell division causing an arrest in the late G2/M 
[204] and cisplatin induces the cell cycle arrest through G1 
-7 and MDA
reated the cells with cisplatin or paclitaxel for 
-7 cells and 72% of MDA-MB-231 cells were detected in 
-7 cells in the G1 stage constitute 41% of the whole 
 
-MB-231 
 cisplatin for 48 
 
 
G2) [203]. 
-MB-231 
 Figure 3. 3. Cell cycle analysis in response to paclitaxel/cisplatin treatment. MCF
MDA-MB-231 cells were treated with 
hours, then fixed and labeled with propidium iodide for FACS analysis.
3.3. Expression of Bc
 It was previously reported that paclitaxel treatment in myeloid leukemia cells 
and cisplatin treatment in thoracic cancer cells can induce both extrinsic and intrinsic 
apoptotic pathways [206
type-dependent, we checked the expression of Bcl
major intrinsic apoptosis regulators. To elucidate the expression pattern of Bcl
proteins, MCF-7 and MDA
then total cell lysates were subjected to immunoblotting using specific antibodies 
indicated (Figure 3. 4). 
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-207]. Because the effects of chemotherapeutics are 
-2 family proteins which compose the 
-MB-231 cells were treated with paclitaxel or cisplatin, and 
 
-7 and 
 
 
highly cell 
-2 family 
  
Figure 3. 4. The expression of Bcl
MCF-7 and MDA-MB
and total cell lysates were subjected to immunoblotting. 
analysis were given as numbers below the related bands. 
 
 The results showed that proapoptotic members, Bax, Bim, 
were upregulated in both cell lines and drug treatments. However, the increase in their 
expression was more prominent in cisplatin treated cells. Moreover, anti
members, Bcl-2, Bcl-xl and Mcl
cells following cisplatin treatment. In MDA
not indicate a significant change, Bcl
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-231 cells were treated with paclitaxel or cisplatin 
The results of the d
β-Actin was used as a loading 
control. 
Puma, Bik and Bad, 
-1, were all downregulated in chemos
-MB-231 cells, while Bcl
-xl and Mcl-1 were downregulated upon cisplatin 
 
for 48 hours 
ensitometric 
-apoptotic 
ensitive MCF-7 
-2 expression did 
 treatment. On the other hand, paclitaxel treatment did not demonstrate
distinct as in cisplatin treated cells according to densitometric analysis.
 
 As mentioned before, FOXO3 is known as the transcriptional regulator of Puma 
and Bim. It was previously reported that MCF
than MDA-MB-231 cells which may influence the cell death response in response to 
several chemotherapeutics 
experimental setup, we obtained total cell lysates from MCF
for immunoblot analysis and detected at least 2
MB-231 cells than MCF
Figure 3. 5. Expression of FO
were isolated from the cells under normal conditions and immunoblotted with anti
FOXO3 antibody. β
 
 Previously, a study with a special focus on FOXO3
breast cancer cells was published showing the upregulation of FOXO3 following 24
hour paclitaxel treatment 
activation in early time points in order to study the effect of NFκB pathway on FOXO3. 
Thus, according to our data and published other studies, we eliminated paclitaxel and 
used only cisplatin as a chemotherapeutic drug for further experiments.
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-paclitaxel relatio
[162]. The aim of our research was to investigate FOXO3 
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3.4. Transcriptional upregulation of DA damage protein GADD45α 
 Cisplatin mainly induces the formation of DNA adducts which lead to activation 
of DNA repair mechanism. Although low concentrations of cisplatin can be 
compensated by this repair mechanism within the cells, the amount used in 
chemotherapy generally causes irreversible DNA damage triggering the cell death 
signaling. However, in chemoresistant cancer cells, sequential mutations occurred 
during carcinogenesis and uncontrolled cell divisions may cause a downregulation in 
DNA repair and cell cycle check point control. GADD45α is a DNA damage response 
and growth arrest protein that can be induced by cisplatin [169, 208-209]. It is also 
directly activated by p53 and FOXO3 upon cisplatin exposure which then leads to cell 
cycle arrest through the G1 check point [210]. Because cisplatin treatment showed 
consistent data considering FOXO3 targets, to check the transcription of GADD45α 
gene, we performed semiquantitative PCR and quantitative realtime PCR by using a 
specific set of primers to amplify GADD45α mRNA (Figure 3. 6). According to 
semiquantitative PCR and realtime PCR results, cisplatin treatment clearly upregulated 
GADD45α transcription in MCF-7 cells indicating FOXO3 activation. In MDA-MB-
231 cells, GADD45α transcription did not show a significant change in semiquantitative 
PCR results and showed a slight decrease in realtime PCR analysis. 
 
 
 Figure 3. 6. The effect of cisplatin treatment on GADD45α transcription. MCF
MDA-MB-231 cells were treated with cisplatin and total mRNAs were isolated in 
indicated time points. (A)
for GADD45α mRNA. GAP
PCR was performed with triplicates and 
3.5. Cisplatin induces apoptosis in MCF
 To analyze the type of cell death induced by cisplati
cellular levels of autophagy marker protein; LC3, apoptosis markers; cleaved caspase 9, 
cleaved caspase 3, cleaved caspase 7, cleaved PARP, BH3
Bim, Puma and an important tumor suppressor; p53 by immunoblot
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DH was used for loading control. (B) Quantitative realtime 
the results were normalized with GAPDH.
-7 and MDA-MB
n, we interrogated the 
-only Bcl-
ting (
 
-7 and 
 
-231 cells. 
2 family members; 
Figure 3. 7). 
 Figure 3. 7. Cisplatin-induced apoptosis in MCF
treated with 30µM cisplatin for indicated time points. Total cell lysates were analyzed 
by immunoblotting with the antibodies specific to cell death
 
 According to the immunoblotting results, increases in the level of cleaved 
caspase 9, 3, 7 and cleaved PARP indicate that cisplatin treatment induced apoptosis in 
both MCF-7 and MDA
proteins Bim and Puma were upregulated and the level of LC3 forms (LC3
II) did not change significantly after cisplatin treatment. Interestingly, while MCF
cells harboring wild type p53 showed an increase in p53 expression after cisplatin 
treatment, p53 levels in MDA
231 cells have a mutant form of p53 
3.6.
 To investigate the effect of cisplatin on NFκB pathway, cells were treated with 
cisplatin in a time de
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-7 and MDA-MB-231 cells. Cells were 
-related proteins. β
was used as a loading control. 
-MB-231 cells. Additionally, pro-apoptotic FOXO3 tar
-MB-231 cells were also elevated even though MDA
[211]. 
 FκB pathway in response to cisplatin 
pendent manner and total proteins were analyzed by 
 
-Actin 
get 
-I and LC3-
-7 
-MB-
 immunoblotting (Figure 3. 
even 30 min after cisplatin 
affected as fast as in MCF
both cell lines. 
 
Figure 3. 8. Effect of cisplatin on NFκB pathway. MCF
were treated with cisplatin for indicated time points. Total cell lysates were then 
analyzed by immunoblotting using the antibodies against NFκB pathway proteins and 
FOXO3. β
3.7. Cisplatin induces nuclear translocation of FOXO3 in MCF
 The transcription activity of FOXO3 mainly depends on its nuclear shuttling 
upon a stimulus. Because the total protein level of FOXO3 shown in 
indicate its transcriptional activation, cytoplasmic and nuclear protein fractions were 
obtained separately at indicated time points to investigate the localization of FOXO3 in 
MCF-7 and MDA-MB-231 cells (
that FOXO3 was translocated to the nucleus in MCF
treatment. On the other hand, cisplatin treatment did not significantly chan
localization of FOXO3 in MDA
amount of cytoplasmic FOXO3 slightly increased after 15 minutes of cisplatin treatment 
in both cell lines. In our study, a substantial amount of FOXO3 
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treatment, IKK activity in MDA-MB-
-7 cells. Of note, total FOXO3 was slightly upregulated in 
 
-7 and MDA
-Actin was used as a loading control. 
-7 but not in MDA
MB-231 cells 
Figure 3. 9). Immunoblotting results clearly showed 
-7 cells after 1
-MB-231 cells. Additionally, it was observed that the 
had been
231 cells was not 
 
-MB-231 cells 
-
Figure 3. 5 cannot 
-hour cisplatin 
ge the 
 always evident 
 in both nuclear and cytoplasmic fractions of MDA
study [212]. 
 
Figure 3. 9. Cisplatin-induced translocation of FOXO3. Following cisplatin treatment, 
cytoplasmic and nuclear proteins were separately extracted from breast cancer cells at 
early time points and subjected to immunoblotting. β
 
 Following the localization studies, to determine the DNA
FOXO3 in MCF-7 cells, nuclear fractions were subjected to electrophoretic mobility
shift assay (EMSA) by using radioactively labeled FOXO3 consensus oligonucleotides 
(Figure 3. 10). The results showed that nuclear FOXO3 bound to its consensus sequen
in MCF-7 cells and consistent with localization results shown in 
binding ability of FOXO3 did not change in chemoresistant MDA
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-Actin and LaminA/C antibodies 
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-MB
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ce 
Figure 3. 9, DNA 
-231 cells. 
 Figure 3. 10. Cisplatin-
EMSA by incubation with radioactively labeled FOXO3 consensus oligonucleotide 
probes after 1-hour cisplatin treatment or without treatment (P; 
3.8. Transfection of siFOXO3 decreases FOXO3 target gene expression and 
induces 
 The basal level of FOXO3 expression may vary in different cell types and the 
amount of FOXO3 in the cells may constitut
Here, we proposed that high FOXO3 level in MCF
cisplatin chemosensitivity. Thus, we performed RNA interference technique in MCF
cells by using siFOXO3 or non
MDA-MB-231 cells. After siRNA transfection, protein lysates were immunoblotted 
with the indicated antibodies to check FOXO3 expression (
Immunoblotting results showed a significant decrease in FOXO3 level after siRNA 
transfection as in its pro
proliferation assay showed that silencing of FOXO3 promoted the proliferative activity 
of MCF-7 cells (137% proliferation) in agreement with another study on human bladder 
cancer cells [214]. 
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induced FOXO3 activation. Nuclear proteins were subjected to 
the proliferative activity of MCF-7 cells.
e diverse cellular characteristics 
-7 cells might be associated with 
-silencing siRNA to mimic the low level of FOXO3 in 
-apoptotic target proteins Bim and Puma. 
Probe only). 
 
[213]. 
-7 
Figure 3. 11). 
Additionally, MTT 
 Figure 3. 11. Silencing of FOXO3 expression in MCF
transfected with FOXO3 silencing (siF) siRNA, non
untransfected (UT). (A)
silencing effect and downreg
Untransfected MDA-MB
Actin was used as a loading control. 
after 48 hours following transfection
obtained from at least three independent experiments (***=p<0.001).
3.9. FOXO3 silencing inhibits cisplatin
 To understand the role of FOXO3 in cisplatin
transfected, non-silencing siRNA transfected and untransfected cells were treated with 
cisplatin. Cell death response was then assayed by immunoblotting and Annexin
staining (Figure 3. 12). Data showed that 
decrease in caspase 9 cleavage and p53 level, but also significantly diminished 
cisplatin-induced cell death in MCF
role of FOXO3 in cisplatin
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-7 cells. MCF
-silencing (NS) siRNA or left 
 Total cell lysates were analyzed by immunoblotting to confirm 
ulation of FOXO3 target gene expression; Bim and Puma. 
-231 cells were shown for the comparison of FOXO3 levels. β
(B) MTT Cell Proliferation assay was
. The results represent the mean (±SEM) values 
-induced cell death in MCF
-induced cell death, 
silencing of FOXO3 not only caused a 
-7 cells. These results further support the essential 
-induced apoptosis in MCF-7 cells. 
 
-7 cells were 
-
 performed 
 
-7 cells 
siFOXO3 
-V 
 Figure 3. 12. Apoptotic response in siFOXO3 transfected MCF
transfected or Non-silencing siRNA (NS) transfected MCF
immunoblotting using antibodies against cleaved caspase 9 and p53. β
as a loading control. 
transfected MCF-7 cells we
FITC-Annexin
3.10. Overexpression of FOXO3 potentiates cisplatin
 
 In order to further investigate the effect of FOXO3 
response, MDA-MB-231 cells that express relatively low FOXO3 were transfected with 
either wild type FOXO3 encoding expression plasmid or mock vector. Transfected 
MDA-MB-231 cells were then exposed to cisplatin for 48 hours
immunoblotted with the antibodies indicated (
increased the level of Bim and Puma 
in MDA-MB-231 cells. It was also observed in EMSA results that FOXO3 
overexpression increased the amount of FOXO3 bound to DNA in nuclear extracts. The 
results indicate that FOXO3 level is critical for th
death in MDA-MB-231 cells.
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-7 cells. 
-7 cells were analyzed by 
(B) Untransfected, siFOXO3 or non-silencing (NS) siRNA 
re treated with cisplatin for 48 hours and incubated with 
-V, then analyzed by FACS (***=p<0.001).
-induced cell death in MDA
MB-231 cells 
expression level in cell death 
 an
Figure 3. 13). Overexpression of FOXO3 
concurrently with a rise in the cell death response 
e modulation of cisplatin
 
 
(A) siFOXO3 
-Actin was used 
 
-
d cell lysates were 
-induced cell 
 Figure 3. 13. Overexpression of FOXO3 in MDA
cells were transfected with pECE
vector (M) or left untransfected (UT). The effect of 
immunoblotting. (B) Nuclear proteins isolated from transfected cells were subjected to 
EMSA by incubation with radioactively labeled FOXO3 consensus oligonucleotide 
probes after 1-hour cisplatin treatment or without treatment (P; Probe only). 
HA-FOXO3(wt), mock vector (M) transfected of untransfected (UT) MDA
cells were treated with cisplatin for 48 hours and cell death analysis with FITC
Annexin-V staining was 
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-MB-231 cells. (A)
-HA-FOXO3(wt) expression plasmid (F(wt)), mock 
the transfection was analyzed by 
determined by FACS (*=p<0.05, **=p<0.01).
 
 MDA-MB-231 
(C) pECE-
-MB-231 
-
 
 3.11. Overexpression of IKK subunits and their effects on cell proliferation and 
 Activation of the IKK complex is a tightly regulated, highly stimulus
and target-specific event that is essentia
targets. While the reports revealing NFκB
progressively increased in the scientific literature 
relationships became more essential for the therapy strategies. As a starting point, we 
first transfected MCF-7 and MDA
the different subunits of IKK complex (IKKα, IKKβ and I
plasmid. Total cell lysates were immunoblotted with the specific antibodies (HA and 
Flag) to visualize the exogenous expression of the subunits in both cell lines (
14). 
 
Figure 3. 14. Overexpression of IKK subunits. 
were transfected with IKKα, IKKβ or IKKγ expression plasmids and total lysates were 
immunoblotted with Flag or HA specific antibodies. β
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viability 
l for the functions attributed to NFκB and other 
-independent roles of IKK members are 
[215], understanding those complex 
-MB-231 cells with the expression plasmids encoding 
KKγ) along with the mock 
 
(A) MCF-7 and (B) MDA
-Actin was used as a loading 
control. 
-specific, 
Figure 3. 
 
-MB-231 cells 
  Following the successful transfection
treated with cisplatin or left untreated for another 48 hours and subjected to MTT
proliferation/cell viability assay (
 
 The results demonstrated that while overexpression of IKKβ increases cell 
proliferation, IKKγ overexpression appears to inhibit p
suggesting that IKKβ somehow promotes proliferation and the regulatory subunit IKKγ 
has a role in growth inhibition
proliferation, but caused a significant increase in cell viabili
On the other hand, overexpression of IKK subunits did not affect cell viability or 
proliferation in MDA-MB
 
Figure 3. 15. Effect of IKK overexpression on cell proliferation and viability. MCF
and MDA-MB-231 cells were transfected with pCMV
IKKγ or mock plasmids. 
determined by MTT proliferation as
cisplatin for 48 hours and cell viability was detected. 
(±SEM) values obtained from at least three independent experiments (***=p<0.001)
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 of IKK subunits, transfected cells were 
Figure 3. 15). 
roliferation in MCF
. Apparently, transfection of IKK
ty after cisplatin treatment. 
-231 cells. 
 
-IKKβ, pCMV
(A) The proliferative activity of transfected cells 
say. (B) Transfected cells were treated with 
The results represent
-based 
-7 cells 
α did not alter 
 
-7 
-IKKα, pCMV-
was 
 the mean 
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3.12. Differential interaction between FOXO3 and IKKβ 
 To identify the interaction between FOXO3 and IKKβ, we co-
immunoprecipitated endogenous FOXO3 and IKKβ with indicated antibodies and the 
precipitates were subjected to immunoblotting (Figure 3. 16). The results showed that 
IKKβ physically interacts with FOXO3 in MCF-7 cells under normal conditions; 
however, 1-hour cisplatin treatment appears to be adequate for the loss of FOXO3-
IKKβ interaction. Oppositely, this interaction takes place only after cisplatin treatment 
in MDA-MB-231 cells. 
 
 
 
Figure 3. 16. IKKβ interacts with FOXO3. MCF-7 and MDA-MB-231 cells were 
treated with cisplatin for 1 hour or left untreated. Total cell lysates were preincubated 
with G-protein coated beads to clear the cell lysates from proteins that unspecifically 
bind to sepharose beads. The beads alone were subjected to immunoblotting (shown as 
Beads). Cell lysates were pulled down (IP) with anti-FOXO3 or anti-IKKβ antibodies. 
Immunoprecipitates were then captured by sepharose beads and probed with the 
indicated antibody (IB) for the immunoblotting analysis. 
 3.13. IKKβ sequesters FOXO3 in the cytoplasm
 Since MCF-7 and MDA
treatment, we speculated that IKKβ in MDA
inhibiting FOXO3 and accordingly decreasing cell death response. To elucidate the 
importance of the ratio between FOXO3 and IKK
IKKβ expression plasmid and treated with cisplatin for 1 hour or left untreated. Nuclear 
and cytoplasmic protein fractions were then immunoblotted (
indicate that overexpression of IKKβ induced the accumulation of endogenous FOXO3 
in the cytoplasm; moreover, IKK
degradation. 
 
Figure 3. 17. IKKβ sequesters FOXO3 in the cytoplasm. 
transfected with pCMV-
cisplatin for 1 hour. Cytoplasmic and nuclear fractions were subjected to 
immunoblotting with 
controls. (B) MCF-7 cells were cotransfected with pCMV
FOXO3(wt) vectors or with their mock vectors (Mock1; pCMV
Mock2; pECE-HA empty vector). 48 hours after transfection
immunoblotted with anti
57 
-MB-231 cells show different sensitivities to cisplatin 
-MB-231 cells might have a role in 
β, we transfected MCF
Figure 3. 
β expressing MCF-7 cells seemed to promote FOXO3 
 
(A) MCF
flag-IKKβ, mock plasmid or left untransfected and treated with 
the antibodies indicated. β-Actin and LaminA/C were used as 
-flag-IKKβ and pECE
-flag empty vector, 
, cell lysates were 
-FOXO3 antibody to visualize the degradation products. β
Actin was used as a loading control. 
 
-7 cells with 
17). The results 
 
-7 cells were 
-HA-
-
  
 We had found above that IKK
additionally, FOXO3 overexpressing MDA
death response in response to cisplatin. According to the data observed, we 
hypothesized that, after the balance between IKK
because of FOXO3 overexpression, the endogenous level of IKK
inhibit all FOXO3 molecules in FOXO3 overexpressing MDA
find out whether the excess amount of FOXO3 (unbound to IKKβ) can be detected in 
immunoblotting, MDA-
plasmid, exposed to cisplatin for 1 hour and endogenous IKKβ was 
immunoprecipitated. Supernatants were then subjected to immunoblotting along with 
precipitates using anti-FOXO3 polyclonal antibody (
that FOXO3 overexpression causes an increase in cisplatin
of the fact that endogenous IKKβ is unable to capture all FOXO3 proteins. 
Consequently, free FOXO3 mo
its target gene expression as previously shown in 
 
Figure 3. 18. Sequestering FOXO3 is limited to IKK
HA-FOXO3(wt) and mock vector transfected MDA
with anti-IKKβ antibody and then G
immunoprecipitation (L; lysate, S; supernatant, B; beads) were analyzed 
immunoblotting with the help of anti
were shown as a control
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β physically interacted and inhibited
-MB-231 cells showed an increased cell 
β and FOXO3 were diminished 
β might not achieve to 
-MB-
MB-231 cells were transfected with FOXO3(wt) expressio
Figure 3. 18). The results indicate 
-induced cell death because 
lecules are able to translocate to the nucleus and regulate 
Figure 3. 13. 
 
 
β level. Total cell lysates of pECE
-MB-231 cells were first incubated 
-protein coated beads. Fractions of 
-FOXO3 and anti-IKKβ antibodies. IgG fragments 
 (H. Chain; Heavy Chain, L. Chain; Light Chain)
 FOXO3, 
231 cells. Thus, to 
n 
-
by 
 
59 
 
3.14. Chemical inhibition of IKK allows nuclear translocation of FOXO3 in MDA-
MB-231 cells 
 Since the kinase activity of IKKα subunit can also influence FOXO3 inhibition 
and the effect of IKKγ on FOXO3 is not known yet, we have inhibited IKK complex by 
chemical means rather than silencing all subunits by RNA interference. We used IKK 
inhibitor-II which specifically inhibits IKK complex without effecting Akt pathway 
[216]. To find out whether chemical inhibition of IKK complex alters FOXO3 
localization in MDA-MB-231 cells, we treated MDA-MB-231 cells with only IKK 
inhibitor-II and obtained subcellular protein fractions to be subjected to immunoblotting 
(Figure 3. 19. A). The results showed that IKK-II inhibitor promoted FOXO3 
translocation into the nucleus after 1-hour treatment. While cisplatin treatment in MDA-
MB-231 cells does not significantly change the level of active FOXO3 in the nucleus, it 
was increased by cisplatin together with IKK inhibitor-II pretreatment (Figure 3. 19. B). 
These results indicate that inhibition of IKK complex promotes the function of FOXO3 
by inducing its nuclear translocation. The immunoblotting results obtained with the 
antibodies against FOXO3 targets also showed an increase in the expression of Bim and 
Puma after IKK inhibition (Figure 3. 19. C). Interestingly, although Bim and Puma 
levels were increased upon IKK inhibitor-II treatment only, pretreatment of IKK 
inhibitor-II followed by cisplatin downregulated Bim and Puma (data not shown). 
Conversely, the cells exposed to IKK inhibitor-II and cisplatin together showed an 
increased cell death compared to only cisplatin treated cells suggesting that a non-
apoptotic or Bim/Puma-independent cell death process might be involved (Figure 3. 19. 
D). 
 
 Figure 3. 19. Inhibition of IKK activates FOXO3. 
with IKK inhibitor-II for indicated time points and subcellular fractions were subjected 
to immunoblotting. β-Actin and LaminA/C were used as controls. 
cells were pretreated with IKK inhibitor
hour, and then nuclear lysates were analyzed by EMSA with radioactively labeled 
FOXO3 consensus oligonucleotides (P; Probe only, C; Control, I; IKK inhibitor
cisplatin). (C) Total lysates of untreated (shown as C), 
(shown as I) cells were appraised by immunoblotting using anti
antibodies. β-Actin was used as a loading control. 
with only Cisplatin (Cis) or pretreated with IKK inhibitor
(I+ Cis) for 48 hours, and then incubated with FITC
control (shown as C), to determine cell death response (**=p<0.01).
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(A) MDA-MB-231 cells were treated 
(B)
-II (30 minutes) and treated with cisplatin for 1 
IKK inhibitor
-Bim and anti
(D) MDA-MB-231 cells were treated 
-II and treated with Cisplatin 
-Annexin-V, along with untreated 
 
 MDA-MB-231 
-II, Cis; 
-II pretreated 
-Puma 
 
 3.15. Ser-644 residue on FOXO3 is essential for cisplatin resistance in MDA
 It was previously shown that IKKβ is able to phosphorylate Ser
FOXO3. To find out whether this phosphorylation site has a significant role on 
chemoresistance, we made use of a mutant FOXO3 plasmid encoding FOXO3(S644A) 
protein. This mutant protein product has alanine amino acid instead of serine on the 
residue 644 and cannot be phosphorylated by IKK
transfected with mock, FOXO3(wt) or FOXO3(S644A) expression plasmids and 
subjected to MTT cell viability ass
MB-231 cells transfected with FOXO3(S644A) plasmid became significantly cisplatin
sensitive indicating the inability of
due to the absent phosphorylation site. Here, we can specify IKKβ as a regulator of 
chemoresistance in MDA
phosphorylation and inhibition of FOXO3.
Figure 3. 20. Transfection of mutant FOXO3 decreases cell viability in response to 
cisplatin. MDA-MB-231 cells were transfected with either pEGFP
(F(S644A)) or mock (M) vector in addition to untransfected control (U
lysates were immunoblotted with anti
Actin was used as a loading control. (B) MDA
Mock, wild type FOXO3 encoding (F(wt)), mutant FOXO3 encoding (F(S644A)) 
vectors or left untransfected. Cells were analyzed by MTT cell viability assay 48 hours 
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231 cells 
β. MDA-MB
ay (Figure 3. 20). MTT results showed that MDA
 IKKβ for sequestering the mutant variant of FOXO3 
-MB-231 cells which performs its function through 
 
-
-FOXO3 antibody to check the transfection. β
-MB-231 cells were transfected with 
after cisplatin treatment (***=p<0.001). 
-MB-
-644 residue on 
-231 cells were 
-
-
 
FOXO3(S644A) 
T). (A) Total cell 
-
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3.16. FOXO3 overexpression induces autophagy in MDA-MB-231 cells after 
cisplatin treatment 
 To investigate the type of cell death in FOXO3 overexpressing MDA-MB-231 
cells, transfected cells were fixed, permeabilized and labeled with cleaved caspase 3 
monoclonal antibody for FACS analysis (Figure 3. 21. A). While untransfected and 
mock transfections showed active caspase 3 positive cells (29% and 26% respectively), 
cells expressing high level of FOXO3 did not show a significant change in caspase 3 
cleavage after cisplatin treatment (14%). 
 
 To monitor the aspect of caspase 9, the upstream protease of caspase 3, 
FOXO3(wt) plasmid transfected cells were subjected to immunoblotting for the 
detection of caspase 9 cleavage. Results showed a loss of caspase 9 cleavage following 
cisplatin treatment explaining the undetectable cleaved caspase 3. Moreover, cisplatin 
treatment also downregulated Bim and Puma expression indicating the suppression of 
pro-apoptotic signals in FOXO3 overexpressing MDA-MB-231 cells. On the other 
hand, an increase of cytosolic LC3 level (LC3-I) was detected in FOXO3(wt) 
transfected cells under normal conditions, whereas after cisplatin treatment LC3-I 
appeared to be converted to its autophagosome-associating form, LC3-II (Figure 3. 21. 
B). 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3. 21. FOXO3 overexpression diminishes cisplatin
MDA-MB-231 cells were transfected with mock, pECE
left untransfected. After 48 hours of transfection, cells were treated with cisplatin for 48 
hours or left untreated and then incubated with a specific monoclonal antibody against 
cleaved caspase 3. Following required washes, cells were subjected to FITC
anti-rabbit antibody incubation. Stained cells were then analyzed by FACS. 
Untransfected, mock vector or pECE
with cisplatin for 48 hours and total cell lysates were immunoblotted with the antibodies 
against LC3, cleaved caspase 9, Bim and Puma. Densitometry values for respective 
samples (indicated below the bands of cleaved caspase 9 and LC3
with respect 
 
 To visualize autophagosome formation induced by cisplatin, we co
MDA-MB-231 cells with FOXO3(wt) and LC3
with only cisplatin, cisplatin with 3MA (3
left untreated. LC3-GFP dots were displayed by fluorescence microscopy (
22). Cells with autophagic dots were counted a
depending on the threshold value of the control. The results pointed that FOXO3 
overexpression led to an increase in the number of autophagosomes in MDA
cells upon cisplatin and this process can be reversed by aut
treatment. Additionally, it was found that neither cisplatin treatment nor excess amount 
of FOXO3 expression alone was adequate to trigger autophagosome formation in 
MDA-MB-231 cells. In this case, cisplatin acts as an autophagy induce
autophagic cells) rather than a strong apoptotic agent when FOXO3 was overexpressed.
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-induced apoptosis. 
-HA-FOXO3(wt) plasmids or 
-HA-FOXO3(wt) transfected cells were treated 
-II) were normalized 
to the control. β-Actin was used as a loading control.
-GFP expression plasmids and treated 
-Methyladenine, an autophagy inhibitor) or 
nd autophagic cells were determined 
ophagy inhibitor 3MA 
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-conjugated 
(B) 
 
-transfected 
Figure 3. 
-MB-231 
r (43% 
 
 Figure 3. 22. Cisplatin-induced autophagic cell death in FOXO3 overexpressing MDA
MB-231 cells. (A) MDA
pEGFP-LC3 and/or pECE
mock vectors (Mock; pECE
treatment following 3MA 
MDA-MB-231 cells. Cover slides with fixed cells were dyed with DAPI and washed 
three times and then analyzed by fluores
Fluorescence dots of LC3
were counted in at least 100 cells and a
cells transcended the threshold value of the
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-MB-231 cells were grown on cover slides and transfected with 
-HA-FOXO3(wt) expression plasmids along with the required 
-HA empty vector, GFP; pEGFP empty vector). 
pretreatment or only cisplatin treatment was carried out 
cence microscope with required filters. (B) 
-GFP in transfected cells, which represents autophagosomes, 
utophagic cell number was determined by the 
 control.
 
-
Cisplatin 
in 
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3.17. Functional p53 is involved in sequestering FOXO3 in the cytoplasm 
 P53 is one of the most studied and important tumor suppressors that can induce 
cell death independent of its transcriptional activity [217]. Recently, several studies 
reported that p53 is one of the interacting partners of FOXO3 in the transcription 
machinery upon several cell death stimuli [218-221]. Interestingly, p53 was also shown 
as a FOXO3 inhibitor in response to DNA damage in mouse fibroblasts [222]. 
 
 We already know the difference in p53 status of MCF-7 and MDA-MB-231 
cells (MCF-7 has wild type p53, MDA-MB-231 has (R280K) p53 that cannot bind to 
DNA). To monitor the inhibitory effect of p53 on FOXO3, Pifithrin-α (a chemical 
inhibitor against the transcriptional activity of p53) [223], was used in MCF-7 cells. 
Cells were treated with pifithrin-α and/or cisplatin and subcellular localization of 
FOXO3 was analyzed (Figure 3. 23. A). In MCF-7 cells that have functional p53, 
pifithrin-α alone increased the level of FOXO3 in the nucleus after 3-hour treatment and 
cisplatin treatment combined with pifithrin-α resulted in nuclear import of FOXO3. 
Moreover, we transfected MDA-MB-231 cells with p53(wt) expression plasmid or 
mock plasmid and treated with cisplatin. Cellular fractions were again analyzed by 
immunoblotting for FOXO3 localization (Figure 3. 23. B). The results showed that 
when wild type p53 was ectopically expressed in MDA-MB-231 cells, cisplatin 
treatment facilitates cytoplasmic FOXO3 accumulation. 
 
  
Figure 3. 23. The effect of functional p53 on FOXO3 subcellular localization in breast 
cancer cells. (A) MCF-7 cells were pretreat
and subcellular fractions were analyzed by immunoblotting. 
were transfected with pCMV
Then, subcellular fractions were analyzed by imm
 
 Needless to say, p53 status is not the only difference between MCF
MB-231 cells as they have different genotypes. Thus, we tested the same experiment in 
wild type and p53-/- HCT116 colorectal cancer cells that have same genotypic 
background except p53 status. In wild type
treatment did not significantly change the localization of FOXO3, pifithrin
cisplatin combination promoted FOXO3 
cells (Figure 3. 24. A). These results suggest that cisplatin treatment following p53 
inhibition causes the nuclear accumul
cells. Additionally, p53(wt) expression plasmid transfected 
that cisplatin treatment facilitated cytoplasmic FOXO3 accumulation as in MDA
231 cells while cisplatin treatment did not
transfection (Figure 3. 24
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ed with 25 µM of Pifithrin
(B) MDA
-p53(wt) expression plasmid and treated with cisplatin. 
unoblotting. LaminA/C and β
were used as loading controls. 
 HCT116 cells, while only pifithrin
nuclear translocation as observed in MCF
ation of FOXO3 in wild type HCT116 and MCF
p53
-/- HCT116 cells showed 
 change FOXO3 profile before p53(wt) 
. B). 
 
-α and/or cisplatin 
-MB-231 cells 
-Actin 
-7 and MDA-
-α 
-α and 
-7 
-7 
-MB-
  
Figure 3. 24. The effect of functional p53 on FOXO3 subcellular localization in 
colorectal cancer cells. (A)
α or Pifithrin-α and cisplatin. Total cell lysates were extracted at indicated time points 
after treatment and subjected to immunoblotting. 
transfected with wild type p53 encoding expression plasmid (p53(wt)) or mock vector. 
Transfected cells were exposed to cisplatin for indicated time points. Cytoplasmic and 
nuclear lysates were obtained and subjected to immunoblotting. β
 
 To examine the effect of p53 status on FOXO3 localization, we also treated wild 
type and p53-/- HCT116 cells with cisplatin for 1 hour and extracted nuclear and 
cytoplasmic fractions to analyze FOXO3 localization without any further treatment 
(Figure 3. 25. A). Immunoblotting results showed that FOXO3 in 
translocated to the nucleus as in MCF
FOXO3 in p53-/- cells was also si
However, nuclear FOXO3 did not appear to bind its consensus site in wild type 
HCT116 cells according to EMSA results (
in p53-/- cells dramatically showed an elevated DNA binding 
cells. 
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 Wild type HCT116 cells were pretreated with only Pifithrin
(B) p53-/- HCT116 cells were 
-Actin and LaminA/C 
were used as controls. 
p53
-7 cells and subcellular localization of endogenous 
milar to MDA-MB-231 cells after cisplatin treatment. 
Figure 3. 25. B). In contrast, nuclear FOXO3 
compared
 
-
+/+ HCT116 cells 
 to wild type 
  
Figure 3. 25. Subcellular localization of FOXO3 in wild type and p53
(A) HCT116 cells were treated with cisplatin for 1 hour and subcellular fractions were 
subjected to immunoblotting to determine the localization of FOXO3 in response to 
cisplatin. β-Actin and LaminA/C were used as controls. 
untreated cells were subjected to EMSA to analyze active FOXO3 (P; Probe only).
 
 It has been previously demonstrated that IKK inhibitor
231 cells to cisplatin cytotoxicity (
cisplatin and IKK inhibition on wt and p53
demonstrated that loss of p53, differently than non
enhanced the effect of cisplatin on cell death (
 
68 
(B) Cisplatin treated and 
-II sensitized MDA
Figure 3. 19. D). Finally, we examined the effect of 
-/- colorectal cancer cells. The results 
-functional p53 in MDA
Figure 3. 26). 
 
-/- HCT116 cells. 
 
-MB-
-MB-231, 
 Figure 3. 26. Cell death response in HCT116 cells. HCT116 cells were treated with 
cisplatin (Cis) or cisplatin and IKK inhibitor
Annexin-
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-II together (I+Cis). Cells were stained with 
V and death response was determined by FACS. 
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4.  DISCUSSIO AD COCLUSIO 
 In cancer tissues, each cell division might result in the formation of cells with 
aggressive behavior that show rigorous resistance to chemotherapeutics [224]. In this 
study, we intended to find a molecular target responsible for chemoresistance in breast 
cancer cells. We showed here that the direct inhibitory effect of IKKβ on FOXO3 and 
established a signaling mechanism which has an important role in chemoresistance. By 
now, most of the targeted therapies were pointing out NFκB inhibition by IKK; 
however, in this study, we propose that the inhibition of IKK might be a new therapy 
strategy against chemoresistant breast cancer cells. 
 
 Among other FOXO3-regulating kinases such as Akt, AMPK and ERK, IKK 
overcomes the regulatory effects of these kinases on FOXO3. The crosstalk between 
FOXO3 and IKKβ appears to be essential for the final decision of cellular response to 
chemotherapeutics. We investigated that FOXO3 decides the cell fate by switching the 
signaling pathways towards a particular type of cell death: apoptosis or autophagy. 
FOXO3 acts both as a molecular mediator and a regulator of cell death by modulating 
the physiological consequences of activation/inactivation of both apoptosis- and 
autophagy-related genes. 
 
 IKK inhibitor-II is a potent inhibitor of IKK complex and blocks IKK-mediated 
FOXO3 inactivation. When it is used in combination with cisplatin, IKK inhibitor-II 
greatly potentiate the effect of cisplatin through FOXO3 activation on tumor cell growth 
(Figure 3. 19). Additionally, ectopic FOXO3 expression and cisplatin treatment together 
significantly induce cell death of chemoresistant MDA-MB-231 cells, suggesting that 
the dual therapy strategy involving exogenous FOXO3 gene expression with concurrent 
IKK inhibition may be a promising novel gene therapy modality to treat advanced 
breast cancers. Although cancer cells can choose either apoptosis for rapid self 
71 
 
execution or autophagy for generating energy and promoting survival, in each case, they 
ultimately undergo cellular death in response to dual therapy. In addition to cancer, 
identification of FOXO3 signaling may enable the development of specific and rationale 
therapies against pathologic conditions caused by dysregulation of apoptosis and 
autophagy such as neurodegenerative diseases. 
4.1. FOXO3 Stability 
 Although FOXO3 has been studied as a substrate of Akt in most research 
articles, IKKβ was shown to have a significant impact on FOXO3 inactivation in our 
study. Accordingly, inhibition of IKK complex by anti-nemo peptide has been shown to 
induce nuclear localization of FOXO3 in agreement with our results [138]. IKK 
complex not only phosphorylates FOXO3, but also regulates cellular localization and 
stabilization of FOXO3 (Figure 3. 17). Clearly, inhibition of FOXO3 phosphorylation at 
Ser-644 is sufficient to sensitize breast cancer cells to cisplatin cytotoxicity even though 
FOXO3 is a substrate of other potent kinases (Figure 3. 20). In this view, chemical 
inhibition of IKK complex might also promote FOXO3 stabilization independently of 
Akt activity (Figure 3. 19). Therefore, in breast cancer cells with cisplatin resistance, 
IKK inhibitor-II and other specific IKK inhibitors might be good candidates for 
combination therapy with cisplatin to enhance the tumor suppressor activity of FOXO3. 
 
 Besides the fact that the regulatory effect of IKKβ on FOXO3, IKKα has been 
also shown to phosphorylate FOXO3 in vitro [186]. Overexpression studies we 
performed with IKK subunits (Figure 3. 14) had demonstrated the protective effect of 
IKKα in response to cisplatin. However, the activation of IKK complex is known to be 
directional. In unstimulated cells, IKKα inhibits the constitutive kinase activity of 
IKKβ; in stimulated cells, IKKα activity is required for the induction of IKKβ [237-
238]. For this reason, we speculated that IKKβ might be activated by IKKα in the cells 
overexpressing IKKα in response to cisplatin which influenced the cell viability 
indirectly through IKKβ activation. Additionally, statistically significant change was 
not observed in proliferation activity of those cells with elevated IKKα expression 
(Figure 3. 15). 
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 Active ERK was demonstrated to phosphorylate FOXO3 at Ser-294, Ser-344 
and Ser-425 residues and ERK-phosphorylated FOXO3 was shown to be subjected to 
proteosomal degradation leading to chemoresistance. ERK activation also appears to 
promote the cell survival by Bcl-2 upregulation and Bim degradation in cisplatin 
resistant ovarian cancers [239-240]. In this regard, the reason for the difference of basal 
FOXO3 levels in MDA-MB-231 and MCF-7 cells (Figure 3. 5) might arise from the 
high level of basal ERK activity observed in MDA-MB-231 cells compared to MCF-7 
cells under normal conditions [241]. 
4.2. DA Damage and p53 
 FOXO3, similar to other transcription factors, has also interacting partners 
which determine the gene specificity on transcription machinery. It is involved in the 
induction of GADD45α transcription together with its well known partner p53 [169, 
230]. It has been shown that the activation of GADD45α transcription occurs only in 
cells having a wild type p53 according to the published studies [210, 231]. In our 
experiments, we demonstrate the absence of GADD45α transcriptional upregulation in 
MDA-MB-231 cells harboring mutant p53, while MCF-7 cells show a distinct 
upregulation in GADD45α mRNA level upon cisplatin exposure (Figure 3. 6). The 
findings suggest a mutual relationship between FOXO3 and p53 in GADD45α gene 
regulation. However, the effectiveness of expressed GADD45α protein in DNA repair 
mechanism is yet to be investigated. 
 
 Puma is another target gene for both FOXO3 and p53; however, transcription of 
Puma by FOXO3 is not necessarily p53-dependent as reported previously [232]. 
Although mutant p53, in theory, has a dominant negative (DN) effect on wild type p53; 
previous studies indicated the promoter selective DN effect of this mutant rather than 
acting as DN for all p53-regulated genes [233-235]. On this account, the direct or 
indirect regulatory effect of mutant p53 on FOXO3 remains uncertain. Moreover, a 
study has demonstrated that the loss of p53 enhances the catalytic activity of IKKβ 
introducing the inhibitory effect of p53 on IKKβ [236]. Hence, cellular response to 
73 
 
chemotherapeutic agents may also depend on this regulatory system (p53-IKK) rather 
than p53-FOXO3 partnership. 
4.3. FOXO3 Expression 
 While the regulation of FOXO3 activity has been extensively studied, the 
control of FOXO3 gene expression is largely unknown. As examined in our study, the 
expression level of FOXO3 is likely to play a crucial role to determine the cellular 
response to cisplatin. A recently published report revealed that p53 transactivates 
FOXO3 by binding to the second intron of FoxO3 gene which is associated with 
extreme longevity in humans [242]. Plus, we observed p53 upregulation (Figure 3. 7) 
and a slight increase in FOXO3 expression in total lysates which is also detectable in 
the cytoplasmic fractions following cisplatin treatment (Figure 3. 9). In addition to the 
report mentioned above, our investigation shows that loss of FOXO3 impairs the 
stabilization of p53 protein (Figure 3. 12). In contravention of their genotypic 
differences, mutant p53-containing MDA-MB-231 cells and p53-/- HCT116 cells have 
shown no difference on the localization of FOXO3 upon cisplatin treatment, on the 
other hand, the ectopic expression of functional p53 in these cell lines has induced the 
cytoplasmic accumulation of FOXO3 (Figure 3. 23 and Figure 3. 24). Accordingly, it 
seems conceivable that FOXO3 and p53 might regulate each others’ stabilization as a 
feedback mechanism. 
 
 FOXO3 has also been shown to induce autophagy in muscle cells via LC3 and 
Bnip3 which displaces Beclin1 from Bcl-xl [165]. In our study, it is apparent that 
FOXO3 level is a critical factor since deviations from IKKβ-FOXO3 balance (Figure 3. 
18 and Figure 3. 13) lead cells to either apoptotic or autophagic cell death (Figure 3. 21 
and Figure 3. 22). FOXO3, being a key protein that can switch the stimuli to a specific 
type of cell death, is most likely regulated by other posttranslational modifications that 
can interfere its function in transcription. Acetylation, for instance, has also profound 
roles in nuclear shuttling and transcriptional activation/repression of FOXO 
transcription factors. SIRT1 is known to be responsible for FOXO3 deacetylation which 
promotes chemoresistance in most cases [243-244]. A previous study showed that 
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deacetylation of FOXO3 by SIRT1 induces cell cycle arrest proteins such as p27KIP1 
and GADD45α; however, this deacetylation also decreases the level of proapoptotic 
FOXO3 target Bim [181]. These findings indicate that SIRT1 deacetylation of FOXO3 
does not inevitably repress FOXO3 function, but in the end, gene selection of FOXO3 
appears to support chemoresistance ultimately upon such a deacetylation. In our study, 
we show a rise in the LC3-I, Bim and Puma protein levels when FOXO3 is ectopically 
expressed. However, cisplatin treatment significantly decreases Bim and Puma protein 
levels while LC3-I is converted to its lipidated form for autophagosome formation 
(Figure 3. 21. B). These autophagic vesicles may be the reason of the decrease in Bim 
and Puma levels since the autophagic vesicles can contain organelles, such as 
mitochondria, in order to degrade the macromolecules within. 
 
 In chemoresistant cells, the absence of functional p53 may result in SIRT1 
activation which enhances the resistance through survival or autophagic gene expression 
by FOXO3. Considering FOXO3 as a partner of p53 in the transcription machinery, 
upregulation of proapoptotic FOXO3 target proteins may also require p53 because 
functional p53 inhibits SIRT1 activity [245]. In our study, we mostly focused on 
expressed target proteins involved in apoptosis and autophagy. However, the extensive 
functionality of FOXO3 in the transcriptional regulation of autophagy-related genes 
needs to be further investigated to clarify how autophagy is initiated. 
 
 A delicate molecular network including p53, IKKβ and FOXO3 seems to 
determine chemoresistance/chemosensitivity in breast cancer cells (Figure 4. 1). In 
sensitive cells, functional p53 and IKKβ inhibits activity of FOXO3 under normal 
conditions. Cisplatin treatment causes nuclear translocation of FOXO3 leading to bim, 
puma upregulation and apoptosis. In resistant cells, on the other hand, cisplatin 
treatment induces IKKβ which triggers FOXO3 phosphorylation on Ser-644 residue and 
its degradation. FOXO3 overexpression (excess FOXO3) in chemoresistant cells 
triggers autophagic cell death. Moreover, functional p53 seems to inhibit FOXO3 action 
in both cells. 
 
  
Figure 4. 1. The proposed mechanism with FOXO3
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-IKKβ crosstalk.
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4.4. Hormone Signalling 
 
 In chemoresistance, as well as in tumorigenesis, hormone signaling and 
associated receptors actively influence the cell fate. FOXO transcription factors were 
first identified as insulin-regulated factors and the important role of FOXOs in human 
longevity mainly takes the root from this insulin signaling pathways. Regarding its 
target proteins, FOXO3 also activates the genes responsible from anti-oxidative defense 
and eliminates the effects of oxidative stress, oxidative stress-related mutations and 
prevents tumorigenesis. In cancer cells, however, this defense system becomes an 
important element in chemoresistance by compensating drug-derived oxidative stress. 
In our study, we observed a reduced oxidative stress in siFOXO3 transfected cells 
following cisplatin treatment supporting the protective effect of FOXO3 in cancer cells 
(data not shown). 
 
 In a variety of animals including mice, rats and hamsters, administration of 
estrogen increases the incidence of cancers in a number of different organs [225]. 
Estrogen receptors are overexpressed in about 70% of breast cancer cases but the exact 
mechanism of its effect on tumor formation is still not fully understood [226]. Two 
hypotheses with evidence suggest that either (1) estrogens promote mammary cell 
proliferation through estrogen receptors and leads to DNA replication followed by 
mutations, or (2) increased activity in estrogen metabolism produces genotoxic 
compounds that cause mutations. In the end, both hypothetical processes result in tumor 
formation by disruption of cell cycle, apoptosis and DNA repair. Additionally, 
accumulating data in breast cancer studies indicate that silencing of FOXO3 promotes 
tumor progression and cisplatin resistance by repressing ER function [227-228]. MCF-7 
cells have estrogen receptor and high FOXO3 expression; on the other hand, MDA-MB-
231 cells have low FOXO3 with undetectable estrogen receptor expression. Thereby, in 
the present study, we show the increased rate of proliferation following FOXO3 
silencing (Figure 3. 11) which further supports the involvement of FOXO3 in tumor 
formation and chemoresistance in addition to the other published reports [229]. 
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4.5. Future Studies 
 The research presented in this thesis seems to have raised more questions than it 
has answered. There are several lines of research arising from this work which should 
be pursued. 
 
 In this thesis we mainly focused on the general outcome of FOXO3 and IKK 
interaction in cell death response; however, there are several potential key proteins in 
cell death regulation which might be actively involved in the switch mechanism 
between apoptosis and autophagy. Since FOXO3 regulates more metabolic genes than 
death-related genes in response to metabolic stress, it is also important to focus on 
physiologic conditions such as diabetic stress and starvation for investigating the 
consequences of changes in metabolic pathways regulated by FOXO3 [184]. 
 
 Furthermore, the role of p53 on FOXO3 regulation should be investigated in 
detail. Although several studies on p53 function have been published, very limited 
number of studies exists on p53 and FOXO3 cooperation. Because most of the 
transcription factors are also involved in the gene regulation independently from their 
DNA binding ability -which determines the “fine-tune” in transcriptional regulation-, 
this line of research will allow us to understand the transcription machinery more 
accurately. 
 
 Finally, it is our intention to investigate thoroughly the crosstalk between 
FOXO3 and NFκB pathway in other cancerous and healthy cell lines with a view of 
explaining how different physical interactions can affect proliferation and cell death 
signaling. Needless to say, mRNAs of FOXO3 and IKKβ can be spliced alternatively in 
different cell lines (transcript variants) which might have an effect on protein-protein 
interactions in signaling pathways. After extensive studies incorporating numerous cell 
lines, the nature of this crosstalk and structural properties of the expressed proteins can 
be incorporated to chemotherapeutic design. 
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APPEDIX A 
Chemicals and media (in alphabetical order) 
 
ame of Chemical    Supplier Company   Catalog # 
2-Mercaptoethanol   Fluka, Switzerland   63700 
Acetic acid    Sigma, Germany   27225 
Acetone    Sigma, Germany   179124 
Acrylamide/Bis-acrylamide   Sigma, Germany    A3699 
Acrylamide/Bis-acrylamide   Biorad, USA    161-0146 
Agarose    Sigma, Germany,   A5093 
Ammonium persulfate   Sigma, Germany    A3678 
Ampicillin-Na salt   Serva, Germany   13399 
Antibiotic solution    Sigma, Germany    P3539 
ATP (Gamma-32P)   Izotop, Hungary   SBP301 
Boric acid    Sigma, Germany   B6768 
Bradford solution    Biorad, USA     500-0006 
BSA     Amresco, USA   0332 
BSA     Promega, USA   R396D 
Chloroform     Sigma, Germany    C2432 
Cisplatin (3,3M)   Bristol Myers Squibb, USA 
Coomassie Brilliant Blue   Merck, Germany    115444 
DAPI     Roche, Germany   10236276001 
Developer/Replenisher  Agfa, Belgium   G150 
Dulbecco’s MEM (DMEM)   Pan, Germany    P04-04510 
DMSO     Sigma, Germany    D2650 
DTT      Sigma, Germany    D9779 
EDTA     Riedel-de Haén, Germany   27248 
Ethanol     Riedel-de Haén, Germany   32221 
Ethidium Bromide    Merck, Germany    OCO28942 
Fixer E.O.S.    Agfa, Belgium   EKSSH 
Foetal Bovine Serum    Pan, Germany    P30-1902 
L-glutamine    Sigma, Germany   G7513 
101 
 
(Appendix A continued) 
 
ame of Chemical    Supplier Company   Catalog # 
G-25 sephadex quick spin column Roche, Germany   11273949001 
Glycerol     Riedel-de Haén, Germany   15523 
Glycine     Molekula, UK    M10795755 
HCl      Merck, Germany    100314 
HEPES     Molekula, UK    M55704197 
Hyperfilm ECL    Amersham, UK    RPN2114K 
IKK inhibitor-II   Calbiochem, USA   401474 
Isopropanol     Riedel-de Haén, Germany   24137 
Kanamycin-sulfate   Applichem, Germany   A1493 
KCl      Amresco, USA    0395 
KH2PO4     Riedel-de Haén, Germany   04243 
KOH      Riedel-de Haén, Germany   06005 
Liquid nitrogen    Karbogaz, Turkey 
Luria Agar     Sigma, Germany    L-3147 
Luria Broth     Sigma, Germany    L-3022 
Methanol     Riedel-de Haén, Germany   24229 
3-Methyladenine   Sigma, Germany   M9281 
McCoy’s 5A     Pan Biotech, Germany  P04-05500 
MgCl2     Sigma, Germany    M9272 
Milk Diluent concentrate   KPL, USA     50-82-00 
Na2HPO4    Merck, Germany   7558-79-4 
NaCl      Duchefa Biochemie, Natherlands  S05205000 
NaO2C2H3.3H2O    Riedel-de Haén, Germany   25022 
NaOH      Merck, Germany    106462 
NaPO4H2     Riedel-de Haén, Germany   04269 
NP-40      Sigma, Germany    I3021 
Paclitaxel/Taxol (7,2mM)  Bristol Myers Squibb, USA 
Paraformaldehyde   Aldrich, Germany   15,812-7 
Penicilin/Streptomycin   PAN, Germany    P06-07100 
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(Appendix A continued) 
 
ame of Chemical    Supplier Company   Catalog # 
Phenol     Applichem, Germany   A1153 
phoSTOP phosphatase inhibitor  Roche, Germany    4906837001 
Pifithrin-α    Sigma, Germany   P4359 
PMSF      Sigma, Germany    P7629 
Poly dI/dC     Sigma, Germany    P4929 
Propidium iodide    Sigma, Germany    P4170 
Protease inhibitor coctail tablet  Roche, Germany    4693124001 
Protein G sepharose beads  Sigma, Germany   P3296 
PVDF membrane   Roche, Germany   03010040001 
Sodium Dodecyl Sulphate   Sigma, Germany    L4390 
TEMED     Sigma, Germany    T7024-100ml 
Triton X-100     Applichem, Germany   A1388 
Tris      Molekula, UK    M11946779 
Tween® 20     Molekula, UK    18945167 
X-ray Film Biomax MS-1  Sigma, Germany   Z36,305-7 
X-ray film    Sigma, Germany   F5388 
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APPEDIX B 
Antibodies and enzymes (in alphabetical order) 
ame     Supplier Company   Catalog # 
Anti-β-Actin    Sigma, Germany   A1978 
Anti-Bad    Cell Signaling, USA   9292 
Anti-Bax    Cell Signaling, USA   2772 
Anti-Bcl2    Cell Signaling, USA   2872 
Anti-Bcl-xl    Cell Signaling, USA   2762 
Anti-Bik    Cell Signaling, USA   4592 
Anti-Bim    Cell Signaling, USA   2819 
Anti-Cleaved Caspase 3   Cell Signaling, USA   9664 
Anti-Cleaved Caspase 7   Cell Signaling, USA   9491 
Anti-Cleaved Caspase 9   Cell Signaling, USA   9501 
Anti-Cleaved PARP    Cell Signaling, USA   5625 
Anti-Flag    Sigma, Germany   F3165 
Anti-FOXO3    Cell Signaling, USA   9467 
Anti-HA    Sigma, Germany   H3663 
Anti-p-IKKα/β   Cell Signaling, USA   2678 
Anti-IκB-α    Santa Cruz, USA   sc847 
Anti-p- IκB-α    Santa Cruz, USA   sc8404 
Anti-IKK-β     Cell Signaling, USA   2684 
Anti-Lamin A/C   Cell Signaling, USA   2032 
Anti-LC3    Cell Signaling, USA   4108 
Anti-Mcl-1    Cell Signaling, USA   4572 
Anti-mouse HRP   Cell Signaling, USA   7076 
Anti-p53    Cell Signaling, USA   9282 
Anti-Puma    Cell Signaling, USA   4976 
Anti-rabbit HRP   Cell Signaling, USA   7074 
Anti-rabbit FITC   Abcam, UK    ab6717 
RNase A    Roche, Germany   119915 
T4 polynucleotide kinase   Promega, USA   C131A 
Trypsin-EDTA   Pan, Germany    P10-0231SP 
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APPEDIX C 
Molecular biology kits and reagents (in alphabetical order) 
 
ame     Supplier Company   Catalog # 
AnnexinV-FITC   Alexis, USA    ALX-209-250 
ECL Advance    Amersham,UK   RPN2209 
Fugene6 Transfection reagent Roche, Germany   11814443001 
Genopure plasmid midi kit  Roche, Germany   03143414001 
Hiperfect transfection reagent Qiagen, Netherlands   301705 
Hs_FOXO3A_1_HP siRNA  Qiagen, Netherlands   SI00421092 
Laemmli 2X sample buffer  Sigma, Germany   S3401-10VL 
Metafectene-easy    Biontex, Germany   T090 
MTT (Cell Proliferation Kit I) Roche, Germany   11485007001 
Negative Control siRNA  Qiagen, Netherlands   1027280 
PageRuller plus, protein ladder Fermentas, Lithuania   SM1812 
Quantitech RT Kit   Qiagen, Netherlands   205311 
Quantitech SYBRgreen Kit  Qiagen, Netherlands   204143 
Sensiscript RT   Qiagen, Netherlands   1010892 
T4 DNA kinase Kit   Promega, USA   M4103 
Taq PCR Master Mix Kit  Qiagen, Netherlands   201443 
Trizol     Invitrogen, USA   15596-018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Expression vectors 
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APPEDIX E 
Oligonucleotides (Synthesized in IDT, Belgium) 
 
GADD45α F: 5’-ATA ACT GTC GGC GTG TAC GAG G 
GADD45α R: 5’-GTT TCT GTA ATC CTT GCA TCA GCG 
 
GAPDH F: 5’-CAC CCA TGG CAA ATT CCA TG 
GAPDH R: 5’-TCT AGA CGG CAG GTC AGG T 
 
IGFBP1 F: 5’-ATT GCT AGC AAG CAA AAC AAA CCG CTA GCT TA 
IGFBP2 R: 5’-TAA GCT AGC GGT TTG TTT TGC TTG CTA GCA AT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
107 
 
APPEDIX F 
Buffers and solutions (in alphabetical order) 
 
Annealing buffer 
100mM KAcetate 
30mM HEPES (pH: 7,4) 
2mM MgAcetate 
 
Annexin-V staining buffer 
100µl cell suspension in FACS incubation buffer 
2µl Annexin-V (Alexis) 
 
Blocking solution 
5g nonfat dried milk 
100ml washing solution 
 
Complete lysis buffer 
20 mM Tris-HCl (pH 7.5) 
150mM NaCl 
NP-40 0.5% (v/v) 
1 mM EDTA 
0.5 mM PMSF 
1 mM DTT 
Protease and phosphatase inhibitor mix 
 
DAPI stock solution (1000X) 
10mg DAPI 
10ml ddH2O 
Store at -20°C 
 
DAPI working solution (1X) 
1μl DAPI stock solution (1000X) 
1ml Methanol (Store at +4°C up to 6 months) 
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 (Appendix F continued) 
 
EMSA binding buffer (5X) 
100mM HEPES-KOH (pH: 7,9) 
5mM EDTA (pH 7,9) 
25% (v/v) glycerol 
25mM MgCl2 
0,5M KCl 
10mM DTT (Freshly added) 
 
EMSA incubation buffer (20μl/sample) 
4μl EMSA binding buffer 
1 μl NP-40 
3,45 μl Glycerol (87%) 
1 μl BSA (stock: 1mg/ml) 
1,5 μl poly dI-dC-poly dI-dC (stock: 1μg/μl) 
1 μl radiolabelled oligonucleotide (from 1:20 dilution of column-purified 50 μl elute) 
Add 5-8 μg nuclear protein and adjust to 20 μl 
 
FACS incubation buffer 
10mM HEPES 
140mM NaCl 
2,5mM CaCl2 
pH: 7,4 
 
Immunoblotting washing solution 
100ml PBS (10X) 
900ml ddH2O 
2ml Tween20 (final: 0,2%) 
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(Appendix F continued) 
 
on-denaturing 6% polyacrylamide gel 
24 ml of H2O 
10ml of 1x TBE 
6ml of 40%acrylamide:1% bisacrylamide 
280 µl of 10% APS (w/v) 
36 µl TEMED 
 
Oligonucleotide labeling reaction mix 
10,25 µl of dH2O 
15 µl of oligonucleotide (final: 26,25pmol, stock: 1,75pmol/µl) 
5 µl of T4 kinase buffer (10X) 
15,75 µl of γ-32P-dATP (3000 Ci/mmol) (final: 52,5 pmol 170 µCi) 
4 µl of T4 polynucleotide kinase (final: 20U, stock: 5U/µl) 
10 minutes at 37°C 
 
Paraformaldehyde fixation (stock solution) 
0,4 g of paraformaldehyde 
8 ml of ddH2O 
5 µl of 1M NaOH 
Heat to 70°C mix frequently until complete solubilization (~10 min at 70°C) 
Cool down to room temperature (on ice) 
Adjust volume to 9 ml with ddH2O 
Add 1 ml of PBS 10X and mix. 
Filter solution using a 0.2 µm filter. 
 
Paraformaldehyde fixation (working solution) 
Prepare a 2% paraformaldehyde solution by diluting 4% paraformaldehyde solution in 
PBS. Use the fixative at room temperature 
 
Primary antibody incubation solution 
2ml 5% (w/v) milk blocking solution and 1μg primary antibody 
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(Appendix F continued) 
 
Propidium iodide staining buffer 
1mg Propidium iodide 
60 µl Triton-X100 
Adjust volume to 10 ml with PBS 
Add 10µl Rnase A (stock: 10mG/ml) for each 1ml 
 
Running buffer (10X) 
144,1g glycine 
30,3g Tris 
10g SDS 
Adjust to 1000ml with ddH2O 
 
Secondary antibody incubation solution 
5ml 5% (w/v) milk blocking solution 
1μg secondary antibody 
 
T1 Buffer 
10 mM HEPES-KOH (pH: 7,9) 
2 mM MgCl2.6H2O 
0,1 mM EDTA 
10 mM KCl 
1% NP-40 
1 mM DTT (freshly added) 
0,5 mM PMSF (freshly added) 
Complete protease inhibitors (freshly added) 
 
T2 Buffer 
50 mM HEPES-KOH (pH: 7,9) 
2 mM MgCl2.6H2O 
0,1 mM EDTA 
50 mM KCl 
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(Appendix F continued) 
 
400mM NaCl 
10% (v/v) Glycerol 
1 mM DTT (freshly added) 
0,5 mM PMSF (freshly added) 
Complete protease inhibitors (freshly added) 
 
TBE (10X) 
108g Tris 
55g Boric acid 
40ml EDTA (pH:8.0) 
 
Transfer buffer (stock: 10X) 
144 g glycine 
30.3 g Tris 
Adjust to 1000ml with ddH2O 
 
Transfer buffer (working: 1X) 
100ml Transfer buffer (10X) 
700ml ddH2O 
200ml Methanol 
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APPEDIX G 
Equipments 
 
Autoclave:  Hirayama, Hiclave HV-110, Japan 
   Certoclav, Table Top Autoclave CV -EL-12L, Austria 
Balance:  Sartorius, BP211D, Germany 
   Sartorius, BP221S, Germany 
   Sartorius, BP610, Germany 
   Schimadzu, Libror EB-3200 HU, Japan 
Centrifuge:  Eppendorf, 5415C, Germany 
   Eppendorf, 5415D, Germany 
   Eppendorf, 5415R, Germany 
   Kendro Lab. Prod., Heraeus Multifuge 3L, Germany 
   Hitachi, Sorvall RC5C Plus, USA 
   Hitachi, Sorvall Discovery 100 SE, USA 
Computer Software: FlowJo 7.2.5 
   Image J 1.42q 
   Photoshop CS5 
   Irfanview 4.20 
   Quantity One 4.6.1 
   MS Office 2007 
Deepfreezer:  -80°C, Kendro Lab. Prod., Heraeus Hfu486 Basic, Germany 
   -20°C, Bosch, Turkey 
Distilled water: Millipore, MilliQ Academic, France 
Electrophoresis: Biogen Inc., USA 
   V20-CDC Scie-plas, UK 
Flow cytometer: BD FACS Conto, USA 
Geiger counter: TAEK, Turkey 
Gel Drier:  EC355, E-C Aparatus, USA 
Gel Analyzer:  Las-4000 mini, Luminescent image analyzer, Fujifilm, Tokyo 
   Universal Hood II, Gel Imager, Biorad, USA 
Ice Machine:  Scotsman Inc., AF20,USA 
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(Appendix G continued) 
 
Incubator:  Memmert Modell 300 and 600, Germany 
Laminar Flow: Kendro Lab. Prod., Heraeus, HeraSafe HS12, Germany 
Magnetic Stirrer: VELP Scientifica, ARE Heating Magnetic Stirrer, Italy 
Microliter Pipette: Gilson, Pipetman, France 
   Mettler Toledo Volumate, USA 
   Eppendorf, Germany 
Microscope:  Olympus BX60 
   Olympus IX70 
pH meter:  WTW, pH540 GLP MultiCal, Germany 
Power supply:  Biorad, PowerPac 300, USA 
   Wealtec, Elite 300, USA 
Refrigerator:  4°C, Bosch, Turkey 
Shakers/ mixers: Forma Scientific, Orbital Shaker 4520, USA 
   GFL Shaker 3011, USA 
   New Brusnswick Sci., Innova 4330, USA 
   C25HC Incubator shaker, New Brunswick Scientific, USA 
   Gyro rocker SSL3, Stuart, UK 
   Thermomixer comfort, Eppendorf, Germany 
Spectrophotometer: Schimadzu UV-1208, Japan 
   Scimadzu UV-3510, Japan 
   ND-1000, Nanodrop, USA 
Thermocycler: iCycler Thermal cycler, Biorad, USA 
   Eppendorf, Mastercycler Gradient, Germany 
Water bath:  Huber, Polystat cc1, Germany 
 
